# The Wolverine stack plus ARA-290 for a degenerating disc and sciatica: the evidence at every link

slug: wolverine-stack-ara-290 · https://miscsubjects.com/a/wolverine-stack-ara-290 · category: peptides · tags: peptide, bpc-157, tb-500, ara-290, disc, sciatica, stack, wolverine · updated 2026-08-04T22:08:42.768Z

A worn spinal disc with a burning leg is not one problem. It is a breakdown running in three separate places at once, and the reason people add ARA-290 to the two-compound Wolverine stack is that the third place — the nerve fibres themselves — is the one the first two compounds do not touch.

The evidence state, before the argument. No study in any species has ever given all three compounds together, so the number of people or animals that have taken this stack under measurement is nought. One at a time the three are nothing like each other. ARA-290 has six human studies and 132 people who received the active compound; three of the six missed their main endpoint, the positive results cluster in one disease, sarcoidosis, and not one of the six enrolled a person with a back problem. BPC-157 has five published human studies covering about 130 people, none of them a finished controlled trial in a torn or worn tissue. The seven-amino-acid fragment sold as TB-500 has no human study at all and no established human dose. Two entries were filed on ClinicalTrials.gov in February 2026 by one sponsor, Hudson Biotech: NCT07437547, a 120-person randomised, double-blind, placebo-controlled hamstring trial marked recruiting, and NCT07487363, which names TB-500 and whose own public summary states that it is a fictional example of a registry record. Neither has reported anything. The animal record behind the disc argument is rats, mice and rabbits, and the one experiment that ever combined two of the three found the pair beat neither compound on its own. What has never been measured in a person: any of the three against a squeezed nerve root or a worn disc, and all three together in anything alive.

One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason.

This page sets out what is breaking down, what makes it break down faster, what each of the three compounds is proposed to build back, and how strong the evidence is at every single link. The grades differ enormously between links, and the strongest evidence in the whole stack sits on the compound most people leave out.

## Three things break down in a worn disc, and they break down in order

**The disc dries out.** The soft centre of a spinal disc is mostly water, held there by a large sugar-and-protein molecule called aggrecan that acts like a sponge. At birth that centre is about 90% water. By 60 it is closer to 70%, because the aggrecan gets chopped up and washed out. Less water means less pressure inside, and a disc that cannot hold pressure cannot spread load.

**The outer ring tears.** As the centre flattens, load transfers to the tough fibrous ring around it. That ring is not built to take the load directly, so it splits — small cracks first, then tears that run through to the outside. That is how a worn disc becomes a bulging or herniated one.

**The chemistry turns hostile, and nerves grow in.** Disc cells under load start pumping out two inflammatory signals, TNF-alpha and IL-1beta. Those signals do three things at once. They raise the enzymes that chew up the disc's own scaffolding while lowering the proteins that block those enzymes, so breakdown outruns building. They irritate any nerve root nearby. And they coax pain nerve fibres to grow into a disc that normally has none in its centre at all.

That third step is why worn and painful are different conditions. Plenty of badly degenerated discs never hurt. What makes a worn disc a painful one is chemistry, not the wear.

[[embed:degenerative-disc-disease]]

## The reason the disc cannot fix any of it

The spinal disc is the largest structure in the body with no blood supply of its own. Nothing feeds it directly. Nutrients seep in slowly through the bony end plates above and below, and those plates stiffen and calcify with age, so the supply gets worse exactly as the demand rises.

Every tissue that heals well heals because blood brings oxygen, raw material and repair cells. The disc gets almost none of that. This single fact governs everything that follows: it is why the breakdown mostly runs one way, why swallowed supplements struggle to reach the tissue, and why any serious attempt at rebuilding has to solve the blood supply before anything else can matter.

It is also why BPC-157 — a compound whose main proposed action is growing new blood vessels into damaged tissue — is the one people reach for, and why that reach has never been tested in a disc.

## What speeds the breakdown up, and which of those you control

Most of what drives disc breakdown is fixed: age, the genes you have, injuries you already had. Two are not fixed, and both have better evidence behind them than any compound on this page.

**Body weight.** A Mendelian randomisation analysis — the study design built specifically to separate cause from correlation, by using inherited genetic variation as the exposure — found that higher body mass index raises the odds of disc breakdown, of low back pain, and of sciatica. That is causal-grade evidence, which is a higher grade than anything supporting any of the three compounds here.

**Smoking.** Nicotine narrows the small vessels feeding a tissue that is already starved of blood, and it is directly toxic to disc cells, cutting their repair activity. For a structure whose central problem is nutrition, that is the worst possible input.

The widely repeated line that one pound of body weight equals four pounds on the spine is not a measured law. The genuine four-to-five-fold load spikes recorded inside living discs come from bending and lifting — the leverage of the trunk — not from a body-weight multiplier.

## Three compounds, three different parts of the problem, graded link by link

This is the argument for the three-compound stack, stated as a table so each link can be attacked separately. The grades run A to F and are defined immediately below the table.

| What is breaking down | The compound aimed at it | What that compound is proposed to do, in plain words | Strongest evidence for that link | Grade | What would prove this link wrong |
|---|---|---|---|---|---|
| No blood supply reaching the damaged tissue | BPC-157 | Grow new blood vessels into the injury by switching on the VEGF growth signal and the nitric-oxide system that widens vessels, so oxygen and raw material arrive | Rat Achilles tendon torn off the bone came back attached and mechanically stronger; cut ligament, crushed muscle and severed muscle-tendon join all healed faster than control | D | Counting vessels at the injury site in a controlled animal study and finding no difference against control |
| Repair cells not reaching or not organising | TB-500 | Bind actin, the filament a cell builds and takes apart to change shape, so repair cells can crawl into the wound and lay ordered collagen instead of scar | Rat Achilles repair, 32 animals, 8 per arm, four weeks: higher load to failure than control, p < 0.05; best tissue score, p = 0.016; most ordered collagen under stain | D | Measuring how many repair cells arrive at the wound and finding no increase |
| The nerve fibres themselves damaged and dying back | ARA-290 | Bind a receptor that only appears on tissue that is already injured, switching on a repair programme that regrows small nerve fibres, without raising red cell counts the way its parent hormone does | Randomised, placebo-controlled human trials. Corneal nerve fibre area rose 697 µm² above placebo at 4 mg a day for 28 days, p = 0.012, in 64 people with nerve fibre loss from sarcoidosis; nerve fibre density rose 2.6 fibres/mm² in the abnormal subgroup of a diabetic neuropathy trial, p = 0.02 | B | A randomised trial in a compressed nerve root showing no separation from placebo — which is the trial nobody has run |
| The nerve root chemically irritated by TNF-alpha | BPC-157 and TB-500, weakly | Calm the inflammatory signalling around the root | Rodent anti-inflammatory models only. The strongest available test of this target in humans — blocking TNF-alpha with a monoclonal antibody at the nerve root — produced a null result against steroid | E | Already largely answered against, see below |
| The displaced fragment physically pressing on the nerve | Nothing | No compound in this stack is claimed to move tissue | Not applicable | Not a claim | Any vendor asserting a peptide puts a disc back is making a claim with no mechanism behind it |
| All three compounds together | — | The three steps at once | Nothing. No study in any species has given all three | F | Untested in every sense |

## The grades explained, so the table can be argued with

- **A** — randomised, placebo-controlled human trial in the actual condition on this page. Nothing on this page holds an A.
- **B** — randomised, placebo-controlled human trial in a different condition, with the target tissue measured directly. ARA-290 holds a B, on nerve.
- **C** — controlled animal experiment in the target tissue.
- **D** — controlled animal experiment in a related tissue. BPC-157 and TB-500 both hold a D: their results are in tendon, ligament, muscle and nerve, never in a disc.
- **E** — cells in a dish, or a mechanism argued from a related pathway.
- **F** — no experiment of any kind.

Read the grade column and one thing jumps out. The compound with the strongest evidence is the one usually treated as the optional add-on, and the two compounds the stack is named after are the two graded D. If evidence quality drove what people bought, the ordering would be reversed.

## The nerve is the only link with randomised human evidence behind it

ARA-290, generic name cibinetide, is an eleven-amino-acid piece of erythropoietin — the hormone that tells bone marrow to make red blood cells. It was built by cutting out the section of that hormone responsible for tissue repair while leaving out the section responsible for red cells.

That split works because the two jobs run through two different receptors. Red cell production runs through the classical receptor. Tissue repair runs through a different pairing, which appears on tissue only after it has been damaged and is absent from healthy tissue. So the compound has, by design, almost nothing to bind to in an uninjured body, and it does not thicken the blood the way erythropoietin does.

The pharmacology has one oddity worth understanding, because it looks like a contradiction. A 4 mg injection under the skin peaks at about 3 ng/mL in the blood and is gone in roughly twenty minutes. Yet it is dosed once a day and the effects last for days. The reason is that binding the receptor starts a repair programme inside the cell, and the programme keeps running long after the compound has cleared. Short life in the blood, durable effect in the tissue.

[[embed:ara-290]]

## ARA-290's trials were real, and not one of them enrolled a back

Six human studies exist. One hundred and thirty-two people have received active compound across all of them. Three of the six missed their main endpoint. Here is every one.

| Study | Registration | People | Who was enrolled | Dose | Length | Result |
|---|---|---|---|---|---|---|
| Culver 2017, Phase 2b | NCT02039687 | 64, 16 per arm | Nerve fibre loss from sarcoidosis, with nerve pain | 1, 4 or 8 mg under the skin, daily | 28 days | Hit at one dose only. Corneal nerve fibre area above placebo: 109 µm² at 1 mg (not significant), 697 µm² at 4 mg (p = 0.012), 431 µm² at 8 mg (not significant). Pain in the moderate-to-severe group, p = 0.157, not significant |
| Brines 2015 | NTR3858 | 49 enrolled, 48 analysed | Type 2 diabetes with painful nerve damage in the feet | 4 mg under the skin, daily, self-injected | 28 days, followed 56 | Hit. HbA1c fell 0.16% at day 28 against 0.01% for placebo, p = 0.002. Pain score improved significantly. Nerve fibre density rose 2.6 ± 1.0 fibres/mm² in the 18 people whose baseline was genuinely abnormal, p = 0.02 |
| Dahan 2013 | Single centre, Leiden | 38 | Sarcoidosis with confirmed small nerve fibre loss | 4 mg under the skin, daily | 28 days | Split. Corneal nerve fibre density rose significantly. Skin nerve fibre density rose 0.38 ± 0.48 fibres/mm, 7.2% of baseline, not significant. Symptoms, temperature sensing and walking distance all improved |
| Heij 2012 pilot | No registration number | 22, 12 active | Sarcoidosis with nerve symptoms | 2 mg into a vein, three times a week | 4 weeks | Hit. Symptom score fell 11.5 ± 3.04 against 2.9 ± 3.34 for placebo, p < 0.05. Pain inventory and fatigue improved equally in both arms, so no separation there |
| Cerit 2015 | NCT02070783 | 36 healthy volunteers | Healthy adults, mood-processing model | 2 mg, single dose | One week | Missed. Some change in emotional processing, no effect on mood |
| Diabetic macular oedema | NCT06626971 | — | Swelling at the back of the eye in diabetes | — | — | Terminated |

[[embed:source:s1]]

[[embed:source:s2]]

Three things follow, and all three matter to somebody reading this with a leg that burns.

**The positive results cluster in one disease.** Three of the four hits are in sarcoidosis, where the nerve damage is driven by the immune system attacking the small fibres. That is a different cause from a nerve root squeezed and chemically irritated by a disc.

**The dose that worked is 4 mg a day and the dose above it did not work.** In the Phase 2b, 4 mg separated from placebo and 8 mg did not. A compound whose effect rises then falls as the dose climbs cannot be dosed by guesswork, and the doses people actually take — 250 to 1,000 mcg a day — sit four to sixteen times below the only dose that has ever worked.

**Nobody has run it against a compressed nerve root.** Not in a person, not in an animal. The entire nerve argument for a disc is a read-across from a different disease with a different cause, and read-across is exactly the step that fails most often in drug development.

[[embed:source:s3]]

## The chemical-irritation link is the weakest one, and it has been tested hard

The strongest case for BPC-157 and TB-500 in a disc is usually made on inflammation rather than structure: the argument that they calm the TNF-alpha driven chemistry making the nerve root hurt. That target has been tested in humans, properly, with a far more potent tool than a peptide.

Etanercept is a drug that blocks TNF-alpha directly. Put at the nerve root against epidural steroid in subacute lumbar nerve pain, it lost — steroid beat saline by 1.26 points on leg pain, which did not reach significance, and etanercept did worse than steroid on function by a margin that did. One other trial of 49 patients found separation only at the lowest of three doses, 0.5 mg, with the 2.5 mg and 12.5 mg arms not separating, at a loose significance threshold.

[[embed:source:s24]]

[[embed:source:s4]]

So the most potent, most targeted available block of TNF-alpha at a nerve root produced a null in the best-controlled trial and an upside-down dose response in the one positive trial. Two peptides with weaker, broader, unmeasured effects on the same pathway are proposed to succeed where that failed. That is the ceiling on the inflammation argument, and it is low.

[[embed:what-are-peptides-herniated-disc]]

## Two of the three have been tested together once, and the pair beat neither alone

In July 2026 a Turkish orthopaedic group published the only experiment that has ever put BPC-157 and TB-500 in the same animals and compared the pair against each one alone. Biçer and colleagues, Joint Diseases and Related Surgery, PMID 42542926.

Thirty-two rats. Achilles tendon cut across and surgically repaired. Four weeks of daily injection into the belly cavity, in four groups of eight: nothing, BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, or both. Outcomes were breaking strength on a testing machine plus two scored measures of tissue quality read blind under a microscope.

What it found: TB-500 alone raised breaking strength against control (p < 0.05) and improved both tissue scores (p = 0.016 and p = 0.017), with the most ordered collagen fibres of any group. BPC-157 alone was numerically better than control without reaching significance. And the combination, in the authors' words, "did not confer additional benefits compared to either agent alone."

Their own explanation is that the two probably feed into shared machinery further downstream, so pushing from two directions does not push harder.

[[embed:source:s5]]

That is the single most important negative result for anyone building a stack, and it deserves to be read straight rather than explained away.

## Four ways that result could be wrong for a disc

Each of these names an experiment, not a caveat.

**Wrong tissue.** A stitched rat Achilles has some blood supply. A disc has essentially none, and the whole argument for BPC-157 is about growing vessels where there are none. A combination could be redundant in a tissue that already gets blood and not redundant in one that gets none. The experiment: the same four-arm design in a disc breakdown model.

**One dose of each.** Ten µg/kg of one and 60 µg/kg of the other, and nothing else tried. ARA-290's own human trials show why that matters — 4 mg worked and 8 mg did not, in the same trial. A single pair of doses tests one point, not the surface. The experiment: three dose levels of each, nine combination arms.

**A ceiling in the measurement.** TB-500 alone already hit significance on strength and on both tissue scores. If a stitched tendon at four weeks heals about as well as that model permits, there is no headroom for a combination to show anything, and the null means the ruler ran out. The experiment: repeat with a harder injury — a bigger gap, a delayed repair, an older animal — so the control arm heals badly.

**Four weeks.** Both dosing and measurement stopped at four weeks. Collagen keeps reorganising for months, and the ordered-fibre finding is precisely the kind of result that can diverge later. The experiment: the same design read at twelve and twenty-four weeks.

## All three together has never been tested in anything

No study in any species, at any dose, by any route, has given BPC-157, TB-500 and ARA-290 together. There is no animal experiment, no case series, no registry entry. The three-compound version of this stack rests entirely on the argument that the three act on different things and therefore should not get in each other's way.

That argument has one piece of evidence against it already, and the evidence is on this page: the only time two of the three were tested together, adding the second one bought nothing.

[[embed:wolverine-stack]]

## One February 2026 registry entry could move the evidence base, and its companion declares itself fictional

Two entries naming these compounds were filed on ClinicalTrials.gov in February 2026, both by the same sponsor, Hudson Biotech. A registry entry is a filing by the sponsor; nobody at the registry checks it, and neither entry has posted a result.

| Trial | Compound | People | Design | What it measures | Started |
|---|---|---|---|---|---|
| NCT07437547 | BPC-157 | 120 planned | Phase 2, randomised, double-blind, placebo-controlled. Grade II hamstring strain confirmed on MRI. Under the skin, once daily for 14 days | Days to unrestricted return to sport at 8 weeks; change in injury volume on MRI at day 14, read by radiologists blind to the group | 2 February 2026 |
| NCT07487363 | TB-500 | 80 planned | Phase 1/2, randomised, double-blind, placebo-controlled, stepped dose escalation, in adults with stable atherosclerotic heart disease | Side events at 12 weeks, serious events at 28 days, plus how the body absorbs and clears it | 5 February 2026 |

[[embed:source:s20]]

Take the second row first, because it decides how much weight the first can carry. The public summary of NCT07487363 opens: "This fictional study is an example of a ClinicalTrials.gov-style record." Its dose field says the levels "are not provided in this public example." It is a template, not a trial. The same sponsor filed eight entries of this shape between 2 and 15 February 2026 — covering BPC-157, TB-500, GHK-Cu, MOTS-c, melanotan II, tesamorelin, tirzepatide and retatrutide, one study site each.

The first row is the one that would matter. NCT07437547 has an imaging endpoint read by people who do not know who got what, which would make it the first study capable of saying whether BPC-157 changes the size of a real injury in a real person. Its listed site is Peking University Shenzhen Hospital. It is a hamstring, not a disc, and 14 days, not twelve weeks, so it will not answer the question on this page. It would answer whether the compound does anything measurable in a human body at all, which is the question underneath it — and it answers nothing until it reports.

Three separate orthopaedic and sports medicine reviews published in 2026 — in Sports Medicine, in the American Journal of Sports Medicine, and in the Journal of the American Academy of Orthopaedic Surgeons — audited this same literature independently and landed in the same place: real animal record, absent human record, unregulated products.

[[embed:source:s21]]

[[embed:source:s22]]

## The number any protocol has to beat is the disc's own recovery rate

This is the number most vendor pages leave out and it changes every decision on this page.

A 2024 meta-analysis pooled 31 studies and 2,233 people with a lumbar disc herniation treated without surgery. The overall rate at which the herniation shrank on its own was 70.39%. Broken out by type: 87.77% for a fragment that has broken free, 66.91% for an extrusion, 37.53% for a protrusion, 13.33% for a simple bulge. Counter to intuition, the bigger and more displaced the herniation, the more likely the body removes it.

[[embed:source:s23]]

That is the base rate. Seven in ten resolve with nothing done. Anybody who runs a twelve-week protocol during that window and improves has, on the numbers, a 70% chance of having improved anyway. One person cannot separate those two outcomes, and no amount of conviction about the result changes that.

[[embed:herniated-disc]]

## Seven people with a back problem wrote down what happened

Self-reports are counted here the same way they are counted anywhere on this site: the person had to state an outcome for themselves, commentary and dosing posts with no result attached were excluded, and negative reports are given the same space as positive ones.

Filtering the self-report record to people describing a back, disc or sciatic problem specifically gives seven usable reports.

| Outcome | Count |
|---|---|
| Said it helped | 4 |
| Said nothing changed | 2 |
| Said something got worse | 1 |
| **Total** | **7** |

**Helped — X, @MuroCrypto, 31 July 2026, anecdotal.** "My lowest disc in the lower back is dried out, almost no fluid left, classic herniated disc. Flared up hard in March, could barely sit or stand without pain. Went on for 3 months with zero improvement. In June I ran BPC-157 and TB-500 for about 6 weeks... After 3-4 weeks it already felt better."
[[embed:source:s6]]

**Helped — Reddit, u/kunukxathletix, r/Sciatica, 7 March 2026, anecdotal.** "I tried ever and eventually decided to try injectable BPC 157 and within a few weeks pain started to ease, well this could be random so I continued use after about 6-7 weeks sciatic pain was almost all the way gone."
[[embed:source:s7]]

**Helped — X, @drmarlonperalta, 4 June 2026, anecdotal.** "I've suffered for 10+ years with lower back pain from a herniated disc... A 6-week cycle removed this distraction permanently."
[[embed:source:s8]]

**Helped, with the writer's own warning attached — X, @AJA_Cortes, 26 May 2024, anecdotal.** "Decided to try to taking oral BPC157 at 2000mcg daily. Also got two deep tissue massages, and a chiro adjustment. 7 days later, pain free. Did the BPC157 help? Maybe, maybe not. Im always open to possibility of placebo."
[[embed:source:s9]]

**Nothing changed — Reddit, u/ImNotSchema, r/backpain, 19 August 2025, anecdotal, ran both compounds.** "I also experimented with TB500 and BPC-157 peptides, but saw no improvement. The one thing that actually helped was Prednisone."
[[embed:source:s10]]

**Nothing changed — Reddit, u/Dizzy-Breakfast-9405, r/backpain, 25 April 2024, anecdotal.** "I even tried peptides (BPC-157) for a month, no results."
[[embed:source:s11]]

**Worse — Reddit, u/Miserable_Fan1984, r/backpain, 16 September 2024, anecdotal, herniated disc, ran both compounds.** "I started taking bpc 157 and tb 500 and 500mcg a day to help with healing but I have started to feel worse and have pain going down my leg again."
[[embed:source:s12]]

Seven is too few to mean anything statistically, and four in seven reporting improvement is what a 70% spontaneous shrink rate would produce with no compound involved at all. What the seven do establish is that the negative and the worse outcomes exist, are specific, and are written by people who wanted the opposite result.

The wider self-report set across all injuries — 40 reports, 21 helped, 15 nothing, 4 worse — is counted in full on the two-compound page.

[[embed:wolverine-stack]]

## What people report on ARA-290, which is a much thinner record

Four ARA-290 self-reports were found, and only one of them states an outcome.

[[embed:source:s13]]

The other three: one person two doses into a run for small fibre nerve damage with six to eight weeks left and no result yet, one post quoting the Phase 2b trial numbers rather than personal experience, and one skeptic asking the sharpest question in the whole set — whether repair signalling does anything while the nerve is still being squeezed.

[[embed:source:s14]]

That question has no published answer. Nobody has tested repair signalling against an ongoing mechanical squeeze.

Not one report was found, on any platform, of a person running all three compounds together. The three-compound stack has no human record at all — not a trial, not a case, not a forum post.

## Reconstituting three vials, one arithmetic at a time

All three ship as dry powder in a sealed glass vial. All three are mixed with bacteriostatic water — sterile water with 0.9% benzyl alcohol in it as a preservative, which is what makes it safe to put a needle into the same vial more than once. All three are measured on a U-100 insulin syringe, where 100 marks equal 1 mL, so one mark is 0.01 mL.

Two lines of arithmetic cover all three:

- Concentration in mcg per mL = total mcg in the vial ÷ mL of water added.
- Mcg per mark = concentration ÷ 100.

**BPC-157, 10 mg vial, 2 mL of water.** 10 mg = 10,000 mcg. 10,000 ÷ 2 = 5,000 mcg/mL. 5,000 ÷ 100 = 50 mcg per mark. A 500 mcg dose = 500 ÷ 50 = 10 marks = 0.10 mL.

**TB-500, 10 mg vial, 2 mL of water.** Identical arithmetic: 50 mcg per mark. 500 mcg = 10 marks. 2.5 mg = 2,500 ÷ 50 = 50 marks = 0.50 mL.

**ARA-290, 10 mg vial, 1.25 mL of water.** 10,000 ÷ 1.25 = 8,000 mcg/mL. 8,000 ÷ 100 = 80 mcg per mark. The 4 mg trial dose = 4,000 ÷ 80 = 50 marks = 0.50 mL, which is exactly the volume injected in the diabetes trial. Add 2 mL instead and you get 5,000 mcg/mL, 50 mcg per mark, and 4 mg becomes 80 marks.

| Compound | Vial | Water | Concentration | Mcg per mark | 250 mcg | 500 mcg | 1 mg | 4 mg |
|---|---|---|---|---|---|---|---|---|
| BPC-157 | 10 mg | 2.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 80 marks |
| BPC-157 | 20 mg | 4.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 80 marks |
| TB-500 | 10 mg | 2.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 80 marks |
| ARA-290 | 10 mg | 1.25 mL | 8,000 mcg/mL | 80 | 3.1 marks | 6.25 marks | 12.5 marks | 50 marks |
| ARA-290 | 10 mg | 2.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 80 marks |

Below about five marks the graduations on a U-100 barrel are too close together to read, which is why the dilute ARA-290 fill is the right one if the dose is under a milligram.

Handling notes that apply to all three. Bring the vial to room temperature first. Run the water slowly down the inside wall rather than squirting it onto the powder. Swirl until clear, never shake — shaking tears peptide molecules apart at the air-water boundary and makes them clump, and clumping is the specific mechanism FDA named when it flagged the risk that the immune system reacts to these products. Once mixed, a vial keeps about four weeks in a fridge at 2–8 °C, which is the preservative's specification rather than a stability measurement on these peptides. Never freeze a mixed vial.

## A full day of all three, in marks and millilitres

| Pattern | BPC-157 | TB-500 | ARA-290 | Total marks | Total volume | Injections |
|---|---|---|---|---|---|---|
| Reachable doses | 500 mcg = 10 marks | 500 mcg = 10 marks | 1 mg = 20 marks | 40 | 0.40 mL | 3 |
| ARA at the dose that was actually trialled | 500 mcg = 10 marks | 500 mcg = 10 marks | 4 mg = 80 marks | 100 | 1.00 mL | 3 |
| BPC daily, TB twice weekly, ARA at the trial dose | 500 mcg = 10 marks | 2.5 mg = 50 marks, twice weekly | 4 mg = 80 marks | 90 most days, 140 twice a week | 0.90–1.40 mL | 2, or 3 twice weekly |

All figures assume 5,000 mcg/mL for BPC-157 and TB-500 and 5,000 mcg/mL for ARA-290. Do not mix any two of them in one syringe — different concentrations, different volumes, different schedules, and combining them makes every later adjustment a guess.

Note the second row. Running ARA-290 at the only dose ever shown to work in a person means the third injection is four times the volume of the other two put together.

## Twelve weeks of all three, priced to the dollar

Prices are from named research-chemical vendors, read on 4 August 2026. Nationwide Peptides publishes a range across vial sizes rather than a price per size, so the endpoints are what can be quoted exactly.

- BPC-157: $42.00 smallest listed size (5 mg), $63.00 largest (20 mg).
- TB-500: $38.00 smallest listed size (5 mg), $61.00 largest (10 mg).
- ARA-290: $43.00 at Nationwide Peptides; Luxe Peptides lists 10 mg at $50.00 and 16 mg at $70.00. The arithmetic below uses $50 per 10 mg.

[[embed:source:s15]]

[[embed:source:s16]]

Twelve weeks is 84 days. Every line shown:

**BPC-157 at 500 mcg a day.** 84 × 500 mcg = 42,000 mcg = 42 mg. Buying 20 mg vials: 3 vials (60 mg) × $63 = **$189**. Per day: $189 ÷ 84 = **$2.25**. A 20 mg vial at 500 mcg a day is 40 doses, but a mixed vial only keeps about 28 days, so 12 doses per vial get thrown away — that waste is already in the price.

**TB-500 at 500 mcg a day.** 42 mg. 5 × 10 mg vials × $61 = **$305**. Per day: **$3.63**. Each vial is 20 doses, which fits the four-week window with nothing wasted.

**ARA-290 at 1 mg a day.** 84 mg. 9 × 10 mg vials × $50 = **$450**. Per day: **$5.36**. Each vial is 10 doses, well inside the window.

**ARA-290 at the 4 mg trial dose.** 84 × 4 mg = 336 mg. 34 × 10 mg vials × $50 = **$1,700**. Per day: **$20.24**. Each vial lasts two and a half days.

**Consumables.** Bacteriostatic water, insulin syringes, alcohol swabs: about $40 for a three-compound twelve-week run at retail.

| What is run | Twelve-week materials | Per day |
|---|---|---|
| BPC-157 alone, 500 mcg/day | $189 + $40 = **$229** | $2.73 |
| TB-500 alone, 500 mcg/day | $305 + $40 = **$345** | $4.11 |
| ARA-290 alone, 1 mg/day | $450 + $40 = **$490** | $5.83 |
| ARA-290 alone, at the 4 mg trial dose | $1,700 + $40 = **$1,740** | $20.71 |
| All three, reachable doses | $189 + $305 + $450 + $40 = **$984** | $11.71 |
| All three, ARA-290 at the trial dose | $189 + $305 + $1,700 + $40 = **$2,234** | $26.60 |

The last two rows contain the honest problem with this stack. The compound holding the only randomised human evidence costs more than the other two combined at the dose that was tested, and costs about the same as them at a dose nobody has tested. Most people who buy all three resolve that by running ARA-290 at a quarter to a sixteenth of the trial dose, which means running the strongest-evidenced compound at a strength for which there is no evidence at all.

None of these prices buys a verified product. There is no pharmacy channel for any of the three. A batch-specific purity test and a mass-spectrometry identity report from an independent lab is the only thing standing between a buyer and a vial of something else, and an eleven-amino-acid peptide with a ring-closed front end, which is what ARA-290 is, is not an easy molecule to synthesise correctly.

## Twelve weeks with a worn L5-S1 and a leg that burns

One case, walked all the way through, with money, hours, measurements, decision points and failure conditions written down before anything starts.

**Week 0 — what exists, and what gets measured.** L5-S1 disc dried out and lost height on MRI, a small protrusion touching the S1 nerve root, burning down the back of the left calf into the outer foot. Leg pain 7/10, back pain 4/10. No weakness, no bowel or bladder change, no numbness in the saddle area — those three would be an emergency and would end this plan immediately. MRI already done: $400–$1,800 cash, $250–$400 typical Medicare allowable, 1 hour.

Five baseline measures written down, because a result nobody measured is a result nobody has:
1. Leg pain, 0–10, worst in the last 24 hours.
2. Oswestry Disability Index, a standard back questionnaire, scored out of 100.
3. Straight-leg-raise angle at which the leg pain starts, measured against a wall.
4. Nights woken by pain, per week.
5. Distance walked before the leg forces a stop.

**Weeks 1–12 — the part with human trials behind it.** Load management and progressive exercise, twice weekly for six weeks then weekly. 18 visits at $75–$150 = **$1,350–$2,700**, about 18 clinic hours plus 20 hours of home work. This is the only line on the page supported by randomised human trials in this exact condition, and it also happens to be the biggest line in money and hours. Everything else is added on top of it, never instead.

**Weeks 1–12 — the compounds, if they are run.** BPC-157 500 mcg a day, TB-500 500 mcg a day, ARA-290 1 mg a day, all under the skin of the abdomen, three separate injections. Materials **$984**. Time: about 6 minutes a day for three injections, so 8.4 hours over twelve weeks, plus roughly 35 minutes reconstituting seventeen vials.

**Week 4 — first decision point.** Stopping rule set in advance: if nights woken has not fallen and the straight-leg-raise angle has not gained at least 10 degrees, ARA-290 stops. The reason it is ARA-290 that gets tested first is that it is the most expensive line and the one with the most specific promise — it either does something to nerve symptoms or it does not, and nerve symptoms are the fastest-moving measure on the list. Money saved by stopping there: **$300**.

**Week 6 — second decision point.** If leg pain has not moved at all, the whole compound protocol stops and the money goes to the exercise programme, which continues either way. Money saved: about **$450**.

**Week 8 — the escalation gate.** If leg pain is still 6/10 or above and disability is still above 40, this is where an epidural steroid injection sits in standard practice: $800–$5,000 cash, $161 Medicare allowable, 3 hours including travel and recovery. The pooled evidence gives it about 6 points on a 0–100 leg pain scale short term, which is below the 10-to-30-point range most people would call a meaningful change.

**Week 12 — the state at the end.** Running total: $1,350–$2,700 physical therapy, $984 materials, $400–$1,800 MRI, $0–$5,000 if an injection was used. Total **$2,734 to $10,484**. Patient time: roughly 47 hours. Base-rate expectation, from the 2,233-patient pooled data, is substantial improvement in leg pain for most people over twelve weeks with no compounds at all.

**What would count as failure, written before the start.**
- No movement on nights woken or straight-leg-raise angle at week 4.
- No movement on leg pain at week 6.
- Any new problem: swelling, worse pain in an untreated area, any change in vision.
- New weakness, new numbness in the saddle area, or any bowel or bladder change at any point — stop everything and get seen the same day.
- Relief that arrives inside a week and disappears within two weeks of stopping. That pattern points at irritation settling rather than tissue rebuilt, and it means the compounds bought a symptom holiday, not a repair.

**The week 12 decision.** Disabling leg pain past twelve weeks, with imaging that matches the symptoms, is where surgery stops being premature. Microdiscectomy runs $15,000–$50,000 list, measured at $14,137 above non-surgical care over two years in trial data, and it buys faster relief rather than a better one-year outcome — the recovery rate at a year is the same either way.

## Where United States law puts all three, which is not the same place

None of the three is an approved medicine in the United States. None is banned outright. But their positions differ, and the difference is worth knowing before buying.

**BPC-157 and TB-500** both appear on FDA's public list of bulk drug substances "nominated but withdrawn" — put forward for use in compounded medicines, placed in the agency's category 2 for possible significant safety risks, then pulled by whoever nominated them. FDA's stated concerns are, in its own words, that products containing BPC-157 "may pose risk for immunogenicity for certain routes of administration", and that for the thymosin beta-4 fragment "FDA has not identified any human exposure data" and "lacks important information regarding any safety issues raised by this drug, including whether it would cause harm if administered to humans."

**ARA-290 appears nowhere on those lists.** It was never nominated for compounding at all. That is not a cleaner status — it is a thinner one. It means no regulator has published a safety assessment of it as a compounding ingredient, favourable or otherwise. It did receive orphan drug designation in both the United States and Europe, and then its developer stopped, so there is no late-stage programme and no pharmaceutical supply of it anywhere.

What follows in plain terms:

- No pharmacy can lawfully compound any of the three. None is on the 503A list traditional compounding pharmacies work from, nor the 503B list outsourcing facilities work from.
- On 23–24 July 2026 FDA's Pharmacy Compounding Advisory Committee voted 8–6, one abstention, in favour of allowing BPC-157 and TB-500 to be compounded, against FDA's own written recommendation. That vote is advice. It binds nothing, approves nothing, and the rulemaking it starts realistically runs eight to twelve months.
- "Research use only" printed on a vial is a shipping label. It is not a legal category and it makes nothing safe or lawful to inject.

[[embed:source:s17]]

[[embed:source:s18]]

## One of the three ends a tested athlete's season

Anyone competing under anti-doping rules — collegiate, professional, masters, a national federation, an Olympic pathway — and anyone serving in the United States military needs this before anything else on the page.

- **TB-500 is named on the WADA 2026 Prohibited List**, under S2.3, growth factors: "Thymosin-ß4 and its derivatives e.g. TB-500." Prohibited at all times, in and out of competition, in the harsher non-specified tier. The catch-all in that same clause covers substances affecting "muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity" — the exact reason to take it is written into the ban.
- **BPC-157 is named** under S0, non-approved substances, also prohibited at all times.
- **ARA-290 is not named**, but S0 covers any substance with no current approval by any government health authority for human use, and ARA-290 has none. Treat it as covered.
- Strict liability applies. Intent does not matter and neither does who recommended it. The Canadian Centre for Ethics in Sport imposed a four-year ban on an athlete for BPC-157 and TB-500.
- A sanction does not require a positive test. An admission, a possession finding, or a purchase record is enough.
- The Department of Defense lists BPC-157 on its prohibited supplement ingredients list and states that it is not a dietary ingredient, it is an unapproved drug.

[[embed:source:s19]]

There is no off-season window. Off-season use is a violation.

## What would prove each link wrong

The value of a stack argued as separate links is that each link can be broken separately. Here is what would break each one, with the current state of the evidence beside it.

| Link | Current state | The result that would break it |
|---|---|---|
| Blood supply reaching the disc, BPC-157 | Grade D. Repeated positive results in tendon, ligament, muscle, nerve and spinal cord in rats, mostly from one research group. Nothing in a disc, ever | A controlled animal study in a disc, counting vessels and measuring disc height, showing no difference against control |
| Repair cells crawling in, TB-500 | Grade D. One controlled rat tendon study with 8 per arm. The ligament and skin results used the full 43-amino-acid protein, not the 7-amino-acid fragment that is sold | The rat tendon study repeated at a larger size with no strength difference; or a direct comparison of the fragment against the full protein showing the fragment does nothing |
| Nerve fibres regrowing, ARA-290 | Grade B. Randomised human trials with a measured structural endpoint, in a different disease, never in a compressed root | A randomised trial in a compressed nerve root showing no separation from placebo |
| Chemical irritation calmed, BPC-157 and TB-500 | Grade E, and already damaged. Direct TNF-alpha blockade at the nerve root produced a null against steroid in the best-controlled trial | Nothing further needed — the burden here sits with anyone claiming the peptides beat what etanercept could not |
| The three acting on different things | Grade F. Never tested. The only test of two of them together found the pair beat neither alone | A three-arm animal study — each compound alone, all three together — showing the three-way combination matches the best single agent |
| Anything beating the disc's own recovery | Grade F. 70.39% of herniations shrink on their own | Any protocol that has not been measured against a control group in this condition cannot claim to beat 70% |

Five links. One at grade B, two at D, one at E, two at F. Not one at grade A, because no randomised trial of any of these compounds has ever enrolled a person with a disc problem.

That is the honest state of it. The mechanism argument is coherent, the three compounds genuinely act on different things, and the amount of measurement behind that coherence ranges from real human trials on one link to literally nothing on another.

[[embed:bpc-157]]

[[embed:tb-500]]

[[embed:ara-290]]

[[embed:what-are-peptides-herniated-disc]]

[[embed:wolverine-stack]]


## Sources

1. Culver DA et al. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Phase 2b, NCT02039687. PMID 28475703 — https://pubmed.ncbi.nlm.nih.gov/28475703/
2. Brines M et al. ARA 290 in type 2 diabetes with painful neuropathy — randomised double-blind placebo-controlled trial, NTR3858, full text with pharmacokinetics and adverse events — https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/
3. ClinicalTrials.gov NCT02039687 — Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis. Completed — https://clinicaltrials.gov/study/NCT02039687
4. Cohen SP et al. Epidural steroids, etanercept, or saline in subacute sciatica: a multicenter, randomized trial. Ann Intern Med 2012. PMID 22508732 — https://pubmed.ncbi.nlm.nih.gov/22508732/
5. Biçer O, Adanir O, Güleryüz Y, Balci EC. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg, 23 July 2026. PMID 42542926 — https://pubmed.ncbi.nlm.nih.gov/42542926/
6. X — @MuroCrypto, 31 July 2026 — anecdotal, positive, herniated lumbar disc, ran both compounds — https://x.com/MuroCrypto/status/2083184469956059529
7. Reddit r/Sciatica — u/kunukxathletix, 7 March 2026 — anecdotal, positive, sciatic pain — https://www.reddit.com/r/Sciatica/comments/1rnicr5/pinched_sciatic_nerve/
8. X — @drmarlonperalta, 4 June 2026 — anecdotal, positive, ten years of low back pain from a herniated disc — https://x.com/drmarlonperalta/status/2062565899714925044
9. X — @AJA_Cortes, 26 May 2024 — anecdotal, positive, L5-S1 flare, writer flags placebo himself — https://x.com/AJA_Cortes/status/1794522474702336108
10. Reddit r/backpain — u/ImNotSchema, 19 August 2025 — anecdotal, no effect, ran both compounds — https://www.reddit.com/r/backpain/comments/1mu96us/hlab27_sacroiliitis_on_mri_vs_disc_obliteration/
11. Reddit r/backpain — u/Dizzy-Breakfast-9405, 25 April 2024 — anecdotal, no effect after a month — https://www.reddit.com/r/backpain/comments/1ccysh4/chronic_onesided_thoracic_pain/
12. Reddit r/backpain — u/Miserable_Fan1984, 16 September 2024 — anecdotal, got worse, herniated disc, ran both compounds — https://www.reddit.com/r/backpain/comments/1fi50ar/bpc_157_and_tb_500_for_herniated_disc/
13. X — @NewsDeskOne, 17 July 2026 — anecdotal, positive, ARA-290 for nerve symptoms in the feet — https://x.com/NewsDeskOne/status/2077929820760019113
14. X — @vedichi_, 16 July 2026 — anecdotal, skeptical, names the read-across problem directly — https://x.com/vedichi_/status/2077787145238913472
15. Nationwide Peptides — ARA-290 (cibinetide), BPC-157 and TB-500 research-chemical listings, prices read 4 August 2026 — https://www.nationwidepeptides.com/products/ara-290-cibinetide-peptide/
16. Luxe Peptides — ARA-290 peptide listing, prices read 4 August 2026 — https://luxepeptides.is/ara-290/
17. FDA — Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks, current as of 22 April 2026 — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
18. FDA — 23-24 July 2026 meeting of the Pharmacy Compounding Advisory Committee — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
19. World Anti-Doping Code International Standard — Prohibited List 2026, effective 1 January 2026 — https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
20. NCT07437547 — A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI. Hudson Biotech. Recruiting, started 2 February 2026 — https://clinicaltrials.gov/study/NCT07437547
21. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med, 12 April 2026. PMID 41966639 — https://pubmed.ncbi.nlm.nih.gov/41966639/
22. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev, 1 January 2026. PMID 41490200 — https://pubmed.ncbi.nlm.nih.gov/41490200/
23. Incidence of Spontaneous Resorption of Lumbar Disc Herniation: A Meta-analysis. Clin Spine Surg, 2024. PMID 37559207 — https://pubmed.ncbi.nlm.nih.gov/37559207/
24. Randomized, double-blind, placebo-controlled trial of transforaminal epidural etanercept for symptomatic lumbar disc herniation. PMID 24165696 — https://pubmed.ncbi.nlm.nih.gov/24165696/


---

# The Wolverine stack: BPC-157 and TB-500, the evidence, the dosing arithmetic and the eight-week cost

slug: wolverine-stack · https://miscsubjects.com/a/wolverine-stack · category: peptides · tags: peptide, bpc-157, tb-500, stack, tendon, wolverine · updated 2026-08-04T22:08:38.210Z

The Wolverine stack is two compounds taken at the same time: BPC-157 and TB-500. People run it after a tendon tear, a bad shoulder, a knee that will not settle, a disc that has been hurting for months. The reason they are run together is not that one is stronger. It is that each one is proposed to fix a different step of the same repair job, so the argument goes that they should not overlap.

The evidence state, up front. No controlled study has ever given both compounds to a person, in any condition, so the number of people who have taken the pair under measurement is nought. Separately the two are not equal. BPC-157 has five published human studies covering about 130 people, and not one of them is a finished controlled trial in a torn or worn tissue. The seven-amino-acid fragment sold as TB-500 has no human study at all and no established human dose. Two entries appeared on ClinicalTrials.gov in February 2026, filed by the same sponsor, Hudson Biotech: NCT07437547, a 120-person randomised, double-blind, placebo-controlled hamstring trial marked recruiting, and NCT07487363, which names TB-500 and whose own public summary states that it is a fictional example of a registry record. Neither has reported anything, and a registry filing is not a result. The animal record behind the pairing is rats, mice and rabbits — roughly 150 animal papers for BPC-157, a much smaller tendon and wound literature for the fragment — and the one experiment that ever put both compounds into the same rats found the combination beat neither compound on its own. What has never been measured in a person: the pair, at any dose, in any tissue, for any length of time.

One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason.

This page sets out what each step is, how good the evidence is for each, what happened the one time somebody put both compounds into the same animals, what a run costs to the dollar, and what forty people who tried it wrote down afterwards.

## Two compounds aimed at two different steps of the same repair

Damaged tendon, ligament and disc all repair in the same order. Blood has to reach the damaged spot. Repair cells have to crawl in from the surrounding tissue. Those cells have to lay down new collagen in ordered fibres rather than a random scar. Each step gates the next.

BPC-157 is proposed to act on the first step. In animals it grows new blood vessels into damaged tissue, mostly by switching on a growth signal called VEGF and the nitric-oxide system that widens vessels.

TB-500 is proposed to act on the second. It is a seven-amino-acid piece of a natural protein, thymosin beta-4, and the piece it copies is the part that grabs actin — the protein filament a cell builds and dismantles to change shape and crawl. Bind actin, and the cell's crawling machinery is freed up. A cell that cannot rebuild its own internal skeleton cannot move into a wound at all.

That is the whole logic of the pairing. One opens the supply line, the other moves the workforce down it. Nothing in the pairing addresses a torn fibre mechanically, and nothing in it dissolves a bulged disc.

[[embed:bpc-157]]

[[embed:tb-500]]

## The bottleneck in tendon, ligament and disc is blood, and both compounds are aimed at it

A muscle bruise heals in weeks. A tendon takes months. A spinal disc, in an adult, barely heals at all. The difference is blood supply. Muscle is dense with vessels. Tendon has few. The centre of an adult disc has none — nutrients cross in by seeping through the cartilage end plates, which themselves stiffen and calcify with age.

That single fact is why both compounds are attractive on paper for these tissues and why neither has been shown to work in them. A drug aimed at growing vessels into a structure that has almost no vessels is aimed at the real rate-limiting step. It is also aimed at the hardest possible target, and the harder the target, the more the argument needs measurements rather than mechanism.

## What each one is proposed to build back, and what would prove it wrong

| Compound | What it is proposed to do, in plain words | Strongest evidence behind that | What it adds that the other does not | What would prove it wrong |
|---|---|---|---|---|
| BPC-157 | Grow new blood vessels into damaged tissue and keep the repair cells there alive, so the site gets oxygen and raw material | Rat Achilles tendon torn off the bone and reattached came back mechanically stronger; cut ligament, crushed muscle and severed muscle-tendon join all healed faster than controls | The supply line. TB-500 does not act on the vessel-growth signal | A controlled animal study measuring blood vessel counts at the injury site showing no difference against control, or a human trial in tendon pain showing no separation from placebo |
| TB-500 | Free up the internal scaffolding cells use to crawl, so repair cells reach the wound and lay ordered fibres rather than scar | Rat Achilles repair, 8 animals per arm, four weeks: higher load to failure than control (p < 0.05), better tissue score (p = 0.016), most ordered collagen of any arm under stain | The workforce. BPC-157 does not bind actin | A study measuring cell arrival at the wound showing no increase, or the same tendon model repeated at a larger size with no strength difference |
| The pair together | Both steps at once, on the theory that a supply line without workers and workers without a supply line each stall | One study, in rats, found the combination did not beat either compound alone | Nothing that has been measured | Already partly answered — see the section below |

The evidence grade is the same for both compounds and it is worth naming plainly: controlled animal experiments in the target tissue, no controlled human experiment in any tissue that hurts.

## The strongest single-compound results, best first

| Rank | Finding | Species and model | Numbers | What it establishes |
|---|---|---|---|---|
| 1 | TB-500 raised maximum load to failure in a repaired Achilles tendon | Rat, tendon cut across and stitched, four weeks | 32 rats, 8 per arm, 60 µg/kg/day into the belly cavity, p < 0.05 | The only controlled measurement of mechanical strength for either compound in a repaired tendon |
| 2 | BPC-157 healed a tendon torn off the bone | Rat, Achilles detached from the heel bone | Faster reattachment and greater strength than control | The structural claim in the tissue people buy it for |
| 3 | BPC-157 sped recovery of a cut sciatic nerve | Rat, nerve cut and repaired | Faster return of function than control | The closest thing to a nerve result either compound has |
| 4 | BPC-157 improved recovery after spinal cord injury | Rat, PMID 31266512 | Better function than control, sustained | Shows the compound reaches and acts on nervous tissue given by mouth or by injection away from the site |
| 5 | Full-length thymosin beta-4 healed a cut knee ligament | Rat, ligament cut, 1 µg placed in the gap in fibrin glue | Uniform fibre bundles, significantly greater mechanical strength | The ligament result — but with the full 43-amino-acid protein, placed in the wound, not the 7-amino-acid fragment injected into fat |
| 6 | Thymosin beta-4 closed skin wounds faster | Rat, full-thickness wound | Surface regrown 42% faster at four days, 61% at seven; more collagen, more vessels | The original result the whole thymosin beta-4 literature rests on |

Rows 5 and 6 carry a caveat that changes how they read. They used full-length thymosin beta-4, a 43-amino-acid protein. What is sold as TB-500 is a 7-amino-acid piece of it, residues 17 to 23, with the front end capped. The two are not the same molecule, and FDA wrote that distinction down in July 2026. Reading a full-length result onto a fragment vial is the single most common error in this area.

Three separate orthopaedic and sports medicine reviews published in 2026 — in Sports Medicine, in the American Journal of Sports Medicine, and in the Journal of the American Academy of Orthopaedic Surgeons — went through this same literature independently and reached the same place: the animal record is real, the human record is not there, and the products on sale are unregulated.

[[embed:source:s34]]

[[embed:source:s35]]

## Somebody finally put both in the same rats, and the pair beat neither one alone

In July 2026 a Turkish orthopaedic group published the only experiment that has ever tested BPC-157 and TB-500 together against each one alone. Biçer and colleagues, in Joint Diseases and Related Surgery, PMID 42542926.

The design, in full: 32 rats, Achilles tendon cut across and surgically repaired, then four weeks of daily injection into the belly cavity, split into four groups of eight — nothing, BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, or both together. Outcomes were maximum load to failure on a testing machine, plus two scored measures of tissue quality read under a microscope by people blinded to the group.

The results:

- TB-500 alone raised maximum load to failure against control, p < 0.05.
- TB-500 alone improved the Bonar tissue score, p = 0.016, and the Movin score, p = 0.017.
- Under a collagen stain, the TB-500 group had the most ordered type I collagen fibres.
- BPC-157 alone came out numerically better than control and did not reach significance on total scores.
- The combination, in the authors' own words, "did not confer additional benefits compared to either agent alone."

That is the sentence the stack has to survive. Two compounds sold as a pair, tested as a pair for the first time, and the pair was no better than the better of the two.

The authors' reading is that the two probably converge on shared downstream machinery — that once the repair programme is running, pushing it from two directions does not push it further.

[[embed:source:s1]]

## Four reasons that one experiment does not close the question

Each of these is a real experiment somebody could run, not a hedge.

**One tissue.** The test was a surgically repaired Achilles tendon in a rat. Tendon has some blood supply. The place the stack is most often aimed at — a spinal disc — has almost none, and the argument for BPC-157 is specifically about growing vessels where there are none. The measurement that would answer this: run the same four-arm design in a disc model, or in a tissue with a poorer blood supply than tendon.

**One dose level each.** BPC-157 got 10 µg/kg/day, TB-500 got 60 µg/kg/day, and nothing else was tried. If either compound's effect rises and then falls as the dose goes up — which is normal for signalling peptides and which the ARA-290 human trials actually showed, where 4 mg worked and 8 mg did not — then a single dose pair tests one point on a surface, not the surface. The measurement: a dose grid, three levels of each compound, nine combination arms.

**A possible ceiling.** TB-500 alone already reached significance on strength and on both tissue scores. If a stitched rat tendon at four weeks heals about as well as that model allows, then a combination has no room left to show a difference, and a null result means the ruler ran out, not that the second compound is inert. The measurement: repeat with a harder injury — a larger gap, a delayed repair, or an older animal — so the control arm heals badly and there is space above it.

**Four weeks.** Dosing and measurement both stopped at four weeks. Collagen in a healing tendon keeps remodelling for months, and the ordered-fibre finding is exactly the sort of thing that could diverge later. The measurement: the same design read at twelve and twenty-four weeks.

None of those four is an argument that the combination works. They are the reasons the single null result does not settle it, and each one names the study that would.

## The experiment that would settle it

A single trial would answer more than everything above. Take a tendon or ligament injury model with a poor blood supply and a control arm that heals badly. Run four arms at three dose levels each — nothing, BPC-157, TB-500, both — with 15 to 20 animals per arm rather than 8, dosed under the skin rather than into the belly cavity, because under the skin is how humans take it. Measure load to failure, blood vessel counts at the wound, and ordered collagen, at four weeks and at sixteen. Pre-register the dose grid.

That study costs a fraction of one human trial and nobody has run it.

Nothing has ever tested three of these compounds together, in any species, at any dose. Adding ARA-290 to this pair for nerve pain is set out separately, and the three-compound combination has zero experimental record of any kind.

[[embed:wolverine-stack-ara-290]]

## No person has ever been given this pair in a controlled study

Here is that fact as one row, with what does exist beside it.

| Question | Answer | Basis |
|---|---|---|
| Controlled human trial of BPC-157 and TB-500 together | None, in any condition | Registry and literature searches return nothing |
| Controlled human trial of TB-500 alone by injection | None, by any route | FDA's July 2026 review states it has found no human exposure data for products containing the fragment |
| Controlled human trial of BPC-157 | Five studies exist; the largest musculoskeletal one is a telephone survey | Published record |
| Human trials of full-length thymosin beta-4 | Yes — eye drops for dry eye and for corneal damage, topical gel for pressure sores | These are surface applications of a different molecule |
| Human dose that has ever been established for either | None | No dose-finding study exists for either compound in a person |

[[embed:source:s3]]

## Two registry entries were filed in February 2026, and one of them says it is a made-up example

That last table has a date on it. As of 4 August 2026 ClinicalTrials.gov holds two entries naming these compounds. Both were filed by the same sponsor, Hudson Biotech, both give a start date in the first week of February 2026, and both are marked recruiting. Read that for what it is. A registry entry is a filing by the sponsor. Nobody at the registry checks it, and neither entry has posted a result.

| Trial | Compound | People | Design | What it measures | When |
|---|---|---|---|---|---|
| NCT07437547 | BPC-157 | 120 planned | Phase 2, randomised, double-blind, placebo-controlled. Grade II hamstring strain confirmed on MRI. Injection under the skin, once daily for 14 days, given by study staff | Days until return to unrestricted sport, at 8 weeks; and change in injury volume on MRI at day 14, read by radiologists who do not know the group | Started 2 February 2026 |
| NCT07487363 | TB-500 | 80 planned | Phase 1/2, randomised, double-blind, placebo-controlled, stepped dose escalation. Adults with stable atherosclerotic heart disease | Side events at 12 weeks, serious events at 28 days, plus how the body absorbs and clears it | Started 5 February 2026 |

[[embed:source:s2]]

Now read the second row against its own record. The public summary of NCT07487363 opens: "This fictional study is an example of a ClinicalTrials.gov-style record." Its dose field says the levels "are not provided in this public example." That entry is a template, not a trial, and any page citing it as proof that TB-500 is being tested in people is citing a placeholder. The same sponsor filed eight entries of this shape between 2 and 15 February 2026 — covering BPC-157, TB-500, GHK-Cu, MOTS-c, melanotan II, tesamorelin, tirzepatide and retatrutide, one study site each — and that is the company the first row keeps.

The first row is the one that would matter. NCT07437547 has an imaging endpoint read by people who do not know who got what, which would make it the first study capable of saying whether BPC-157 changes the size of a real injury in a real person. Its listed site is Peking University Shenzhen Hospital.

Neither entry tests the pair. Neither enrols anyone with a back problem. And a filing is not a finding: until NCT07437547 posts results, the number of randomised human results for either compound in a torn tissue stays at zero.

## Forty people wrote down what happened to them, and here is the tally

Self-reports are not evidence of whether a compound works. They are evidence of what happens to people who take it, which is a different and still useful thing — it is where side effects, dose ranges and failure rates show up first, years before anybody runs a trial.

Forty reports were counted. The rule for counting: the person had to state an outcome for themselves. Commentary about the compounds, dosing instructions with no result attached, and posts written mid-run before any outcome were excluded — sixteen entries were dropped on that rule.

| Outcome | Count | Share |
|---|---|---|
| Said it helped | 21 | 52.5% |
| Said nothing changed | 15 | 37.5% |
| Said something got worse | 4 | 10% |
| **Total counted** | **40** | |

Every one of these is anecdotal. None was blinded, none had a control, and people who get a result post more readily than people who do not, so the true no-effect share is almost certainly higher than 37.5%.

### The twenty-one who said it helped

[[embed:source:s4]]

[[embed:source:s5]]

[[embed:source:s6]]

[[embed:source:s7]]

[[embed:source:s8]]

[[embed:source:s9]]

[[embed:source:s10]]

[[embed:source:s11]]

[[embed:source:s12]]

[[embed:source:s13]]

[[embed:source:s14]]

That last one is worth its own line. Pain that vanishes in days and returns within days of stopping is the signature of something calming irritation, not of something rebuilding a tendon. Rebuilt tissue does not un-rebuild in a week. Several of the fast-relief reports fit that shape better than they fit a repair story.

The remaining ten in this group: u/DifficultReach2720 (foot, "basically fully healed" at three months), u/NoInvestigator7249 (elbow, range of motion back to 100%), u/frequentflyernine11 (wrist, close to previous strength after seven vials, still minor pain), u/sdBiotch ("not a miracle by any means but I can improve mobility"), u/SanketJ1986 (pain down in the treated arm, no change in the other), u/Quacka-moo ("It has helped a bit but I expected more"), @drmarlonperalta (ten years of low back pain from a herniated disc, "a 6-week cycle removed this distraction permanently"), @AJA_Cortes (L5-S1 flare, oral BPC-157 at 2,000 mcg a day, pain free in seven days, and his own comment was "maybe, maybe not — I'm always open to possibility of placebo"), @Breedlove22 (ran both, credited the pair), and @mindpumpsal.
[[embed:source:s15]]

[[embed:source:s16]]

### The fifteen who said nothing changed

[[embed:source:s17]]

[[embed:source:s18]]

[[embed:source:s19]]

[[embed:source:s20]]

[[embed:source:s21]]

[[embed:source:s22]]

[[embed:source:s23]]

[[embed:source:s24]]

[[embed:source:s25]]

The other six: u/Dizzy-Breakfast-9405 (a month, thoracic pain, no results), u/kayfab (capsules, ligament, nothing), u/Acrobatic-Car3352 (nine days into a blend, Achilles, no changes), u/forsaken3400 (day 5, shoulder, nothing beyond possibly better sleep), u/mite189 (the tear did not heal faster; recovery came with prescribed isometric work), u/mudra311 (elbow, "I felt better before the BPC as well").

### The four who got a new problem

[[embed:source:s26]]

[[embed:source:s27]]

[[embed:source:s28]]

[[embed:source:s29]]

Two of those four describe swelling or fluid at or near the treated site, and both compounds are proposed to grow blood vessels, which is a mechanism that would produce exactly that. The blurred vision report has no mechanism attached to it and no follow-up.

### What the tally can and cannot decide

It cannot decide whether the compounds work. Half a sample reporting improvement in a condition where most soft-tissue injuries improve on their own over the same weeks is what a completely inert substance would also produce.

It can decide four things. First, roughly one person in ten reports a new problem, and that number belongs in any decision. Second, the doses in real use cluster at 250 to 500 mcg a day for BPC-157, which is well below the milligram doses in every human study of BPC-157 that has been published. Third, the fast-relief-then-relapse pattern is common enough to suggest that much of what people feel is irritation settling rather than tissue rebuilding. Fourth, the failures are specific and repeated — several people ran it three separate times with nothing to show.

## Twelve of the forty ran both compounds, not one

The tally above mixes people who took BPC-157 alone with people who ran the pair. Splitting out only those who explicitly ran both:

| Outcome | Count |
|---|---|
| Helped | 6 |
| Nothing changed | 4 |
| Something got worse | 2 |
| **Total** | **12** |

Six helped out of twelve, against twenty-one out of forty in the whole set. Twelve people is far too small to compare against anything, and a 50% versus 52.5% gap means nothing at that size. What the split does show is that no signal jumps out in favour of running both, which is the same direction the rat study pointed.

## Turning a vial of powder into marks on a syringe

Both compounds ship as a dry white powder in a sealed glass vial, usually 5, 10 or 20 mg. You add bacteriostatic water — sterile water with 0.9% benzyl alcohol in it as a preservative, which is what makes it safe to put a needle into the same vial repeatedly. Plain sterile water works chemically but has no preservative, so it is a one-entry proposition.

The dosing tool is a U-100 insulin syringe. U-100 means 100 marks per millilitre, so one mark is 0.01 mL. Two lines of arithmetic give you everything:

- Concentration in mcg per mL = total mcg in the vial ÷ mL of water added.
- Mcg per mark = concentration ÷ 100.

Worked all the way through, for a 10 mg vial with 2 mL of water:

1. 10 mg = 10,000 mcg.
2. 10,000 mcg ÷ 2 mL = 5,000 mcg per mL.
3. 5,000 ÷ 100 = 50 mcg per mark.
4. A 500 mcg dose = 500 ÷ 50 = 10 marks = 0.10 mL.

| Vial | Water added | Concentration | Mcg per mark | 250 mcg | 500 mcg | 1 mg | 2.5 mg | Doses per vial at 500 mcg |
|---|---|---|---|---|---|---|---|---|
| 5 mg | 1.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 50 marks | 10 |
| 5 mg | 2.0 mL | 2,500 mcg/mL | 25 | 10 marks | 20 marks | 40 marks | 100 marks | 10 |
| 10 mg | 2.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 50 marks | 20 |
| 10 mg | 3.0 mL | 3,333 mcg/mL | 33.3 | 7.5 marks | 15 marks | 30 marks | 75 marks | 20 |
| 20 mg | 4.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 50 marks | 40 |

Adding more water does not change how much compound is in the vial. It changes only how many marks carry a dose. Below about five marks the graduations on a U-100 barrel are too close together to read reliably, which is the practical argument for the more dilute fills when the dose is small.

Handling that ruins the peptide is easy to do by accident. Bring the vial to room temperature first. Run the water slowly down the inside wall rather than squirting it onto the powder. Swirl until clear, never shake — shaking a peptide solution tears the molecules apart at the air-water boundary and makes them clump, and clumping is the exact mechanism FDA named when it raised the risk that the immune system reacts to these products.

Once water is in, a vial keeps about four weeks in a fridge at 2–8 °C. That is the preservative's specification, not a stability measurement on these peptides — nobody has run one. Do not freeze a reconstituted vial; freezing and thawing makes short peptides clump.

## A full day of both compounds, in marks and millilitres

Two common daily patterns, both at 5,000 mcg/mL:

| Pattern | BPC-157 | TB-500 | Total volume | Injections per day |
|---|---|---|---|---|
| Both daily, low | 500 mcg = 10 marks = 0.10 mL | 500 mcg = 10 marks = 0.10 mL | 0.20 mL | 2 |
| BPC daily, TB twice weekly | 500 mcg = 10 marks = 0.10 mL | 2.5 mg = 50 marks = 0.50 mL, Monday and Thursday | 0.10 mL most days, 0.60 mL twice a week | 1, or 2 twice a week |

Do not mix the two in one syringe. They have different concentrations, different volumes and different schedules, and combining them makes every future dose adjustment guesswork.

Where the needle goes was never resolved by the animal work, because the animals were dosed into the belly cavity or by drinking water, almost never at a site chosen to be near an injury. Several of the strongest structural results in rats — cut ligament, muscle torn off bone, spinal cord — came from animals drinking the compound in water and still repairing a specific distant injury. There is no head-to-head study showing an injection near the injury beats an injection into abdominal fat.

## Eight weeks of materials, priced with the arithmetic shown

Prices below are from one named research-chemical vendor, Nationwide Peptides, read on 4 August 2026. They publish a range across vial sizes rather than a per-size price, so the two endpoints are what can be quoted exactly.

- BPC-157: $42.00 for the smallest listed size (5 mg), $63.00 for the largest (20 mg).
- TB-500: $38.00 for the smallest listed size (5 mg), $61.00 for the largest (10 mg).

[[embed:source:s30]]

Eight weeks is 56 days. The arithmetic:

**BPC-157 at 500 mcg a day.** 56 days × 500 mcg = 28,000 mcg = 28 mg.
- Buying 5 mg vials: 6 vials (30 mg) × $42 = **$252**. Cost per day = $252 ÷ 56 = **$4.50**.
- Buying 20 mg vials: 2 vials (40 mg) × $63 = **$126**. Cost per day = $126 ÷ 56 = **$2.25**. Twelve milligrams get discarded, because a 20 mg vial at 500 mcg a day is 40 doses and a reconstituted vial only lasts about 28 days. Even throwing that away, the big vial is half the price of the small ones.

**TB-500 at 500 mcg a day.** 28 mg over the run. 3 × 10 mg vials × $61 = **$183**. Cost per day = **$3.27**. A 10 mg vial at 500 mcg a day is 20 doses, which fits inside the four-week window with nothing wasted.

**TB-500 at 2.5 mg twice a week.** 5 mg a week × 8 = 40 mg. 4 × 10 mg vials × $61 = **$244**. Cost per day = **$4.36**. Each vial is 4 doses, so exactly two weeks per vial.

**Consumables.** Bacteriostatic water, insulin syringes, alcohol swabs: about $30 for a run at retail.

| What is run | Eight-week materials | Per day |
|---|---|---|
| BPC-157 alone, 500 mcg/day, 20 mg vials | $126 + $30 = **$156** | $2.79 |
| TB-500 alone, 500 mcg/day | $183 + $30 = **$213** | $3.80 |
| Both, 500 mcg/day each, cheapest vial sizes | $126 + $183 + $30 = **$339** | $6.05 |
| Both, 500 mcg/day each, smallest vial sizes | $252 + $183 + $30 = **$465** | $8.30 |
| Both, BPC daily + TB 2.5 mg twice weekly | $126 + $244 + $30 = **$400** | $7.14 |

Adding the second compound to a BPC-157-only run costs $183 over eight weeks and doubles the injections. That is the price of the only thing the pairing buys, and the one experiment that measured whether it buys anything found that it did not.

None of these prices buys a verified product. There is no pharmacy channel for either compound, no monograph, and no requirement on any vendor to be accurate. A batch-specific purity test and mass-spectrometry identity report is the only thing standing between a buyer and a vial of something else, and at least one of the reports above — the man who ran 10 mg with no result and wondered whether his source was fake — is exactly that failure mode.

## Twelve weeks with a torn rotator cuff, hour by hour and dollar by dollar

One case, walked all the way through, with the numbers attached and the failure conditions written down before the start.

**Week 0 — what exists.** Partial-thickness rotator cuff tear confirmed on MRI. Pain 6/10 overhead, 2/10 at rest. Cannot sleep on that side. MRI already done: $400–$1,800 cash, $250–$400 typical Medicare allowable, 1 hour. Four things get written down as the baseline, because a result nobody measured is a result nobody has: pain overhead on a 0–10 scale, degrees of pain-free overhead reach measured against a doorframe, nights woken per week, and heaviest weight pressed overhead for five reps.

**Weeks 1–12 — the part that actually has evidence.** Progressive loading, twice a week with a therapist for the first six weeks then once. 18 visits at $75–$150 = $1,350–$2,700, about 18 clinic hours plus 20 hours of home work. This is the arm of the plan with randomised human trials behind it, and it is also the largest line in both the money column and the hours column. Anything else is added on top of it, never instead of it.

**Weeks 1–8 — the compounds, if they are run.** BPC-157 500 mcg a day and TB-500 500 mcg a day, into abdominal fat. Materials $339. Time: about 4 minutes a day for two injections, 56 days, so 3.7 hours over the run, plus roughly 20 minutes total spent reconstituting five vials.

**Week 4 — first decision point.** The stopping rule, set in advance: if nights woken per week has not fallen at all by week 4 and pain-free overhead reach has not gained at least 10 degrees, the compounds stop. That is not a strict test — a rotator cuff on a good loading programme improves over four weeks anyway — but a run showing zero movement on both measures at four weeks has failed its own premise. Money saved by stopping there: $170.

**Week 8 — second decision point.** Compounds end regardless. Both measures are read again. Anything that has improved from here belongs to the loading programme, which is running either way, and that is the point of ending the run while therapy continues — it separates the two.

**Week 12 — the state at the end.** Running total: $1,350–$2,700 in physical therapy, $339 in materials, $400–$1,800 for the MRI, so **$2,089 to $4,839**. Patient time: about 42 hours. The expected result on the loading programme alone, from the trial literature, is substantial improvement in pain and function in most partial-thickness tears at twelve weeks without surgery. The compounds cannot be credited for that, because a single person running one arm cannot separate a treatment from the natural course. What one person can learn is whether they got a side effect, whether they tolerated it, and what it cost.

**What would count as failure.** No change on either baseline measure at week 4. A new problem — swelling, worsening pain in an untreated joint, anything visual. Or pain that improves during the run and returns within two weeks of stopping, which points at irritation settling rather than tissue rebuilt.

## In United States law neither one is a medicine

Neither BPC-157 nor TB-500 is an approved medicine in the United States. Neither is banned outright either. Both sit in a specific and awkward place, and the FDA page that defines it is public.

Both appear on FDA's list of bulk drug substances "nominated but withdrawn" — substances that were put forward for use in compounded medicines, placed in the agency's category 2 for possible significant safety risks, and then pulled by whoever nominated them. FDA's stated concerns, in its own words, are that compounded products containing BPC-157 "may pose risk for immunogenicity for certain routes of administration" and that for the thymosin beta-4 fragment "FDA has not identified any human exposure data" and "lacks important information regarding any safety issues raised by this drug, including whether it would cause harm if administered to humans."

[[embed:source:s31]]

What follows from that, in plain terms:

- No pharmacy can lawfully compound either one. Neither is on the 503A list that traditional compounding pharmacies work from, nor the 503B list that outsourcing facilities work from.
- On 23–24 July 2026 FDA's Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, in favour of allowing BPC-157 and TB-500 to be compounded, against FDA's own written recommendation. That vote is advice. It does not bind FDA, it does not make either an approved drug, and the rulemaking it triggers realistically takes eight to twelve months.
- "Research use only" on a vial is a shipping label, not a legal category that makes anything safe or lawful to inject.

[[embed:source:s32]]

## Both are banned in tested sport, at all times

Anyone who competes under anti-doping rules — collegiate, professional, masters, national federation, Olympic pathway — is exposed, and so is anyone serving in the United States military.

- BPC-157 is named in the WADA 2026 Prohibited List under S0, non-approved substances, prohibited at all times, in and out of competition.
- TB-500 is named under S2.3, growth factors, as "Thymosin-ß4 and its derivatives e.g. TB-500", also prohibited at all times, in the harsher non-specified tier.
- The S2.3 catch-all covers substances affecting "muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity" — the exact reason someone would take either one is written into the prohibition.
- Strict liability applies. Intent does not matter, and who recommended it does not matter. The Canadian Centre for Ethics in Sport imposed a four-year ban on an athlete for exactly this pair.
- Sanctions can be imposed with no positive test at all, on an admission, a possession finding, or a purchase record.
- The Department of Defense lists BPC-157 on its prohibited supplement ingredients list and states plainly that it is not a dietary ingredient, it is an unapproved drug.

[[embed:source:s33]]

Off-season use is a violation. There is no window in which either compound is allowed.

## What is solid, what is a guess, and what nobody knows

**Solid.**
- TB-500 raised the breaking strength of a repaired rat Achilles tendon against control, 8 animals per arm, four weeks, p < 0.05.
- BPC-157 improved healing in rat tendon-to-bone, ligament, muscle, sciatic nerve and spinal cord models, across many separate experiments from largely one research group.
- Tested head to head in rats, the combination beat neither compound alone.
- Neither is an approved medicine, neither is lawfully compoundable, and both are banned in tested sport at all times.
- Doses in real use are 250 to 500 mcg a day, well below every published human dose of BPC-157, which were all milligram doses.

**A guess.**
- That any rat dose translates to a human dose. Scaling the standard rat dose of 10 µg/kg straight to a 70 kg adult gives about 0.7 mg a day, roughly twice what most people take.
- That injecting near the injury beats injecting into abdominal fat. Nothing has compared them.
- That the vial contains what the label says. Nothing requires it to.
- That the two compounds are worth running together. One experiment says no, and it has the limits set out above.

**Nobody knows.**
- What either compound does in a person over months. The longest human exposure on record for BPC-157 is two weeks in a Phase 1 study.
- Whether the immune system reacts to repeated injections of either. FDA named this as its specific concern and no one has measured it.
- What happens if either is taken by someone with an undiagnosed cancer. Both are proposed to grow blood vessels, which is also what a tumour needs, and thymosin beta-4 is overexpressed in many solid tumours.
- Whether the fragment sold as TB-500 does anything the full protein does, outside the one rat tendon study.

For the version of this stack aimed at a worn disc and nerve pain, with ARA-290 added for the nerve itself, the mechanism table, the evidence grades and the three-compound arithmetic are set out separately.

[[embed:wolverine-stack-ara-290]]

[[embed:what-are-peptides-herniated-disc]]

[[embed:degenerative-disc-disease]]

[[embed:ara-290]]


## Sources

1. Biçer O, Adanir O, Güleryüz Y, Balci EC. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg, 23 July 2026. PMID 42542926 — https://pubmed.ncbi.nlm.nih.gov/42542926/
2. NCT07437547 — A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI. Hudson Biotech. Recruiting, started 2 February 2026 — https://clinicaltrials.gov/study/NCT07437547
3. FDA Briefing Document, Pharmacy Compounding Advisory Committee — TB-500-related bulk drug substances, July 2026 — https://www.fda.gov/media/193349/download
4. Reddit r/Biohackers — u/beach_nuts, 8 June 2026 — anecdotal, positive — https://www.reddit.com/r/Biohackers/comments/1u09ium/bpc_157_tb500_side_effect_for_65_yrs_old/oqhs3hp/
5. Reddit r/PEDs — u/SprinklesWise9857, 11 October 2025 — anecdotal, positive, self-assessed — https://www.reddit.com/r/PEDs/comments/1o3g7qp/is_oral_bpc157_less_effective_than_injecting_it/niwej2s/
6. Reddit r/Sciatica — u/kunukxathletix, 7 March 2026 — anecdotal, positive, sciatic pain — https://www.reddit.com/r/Sciatica/comments/1rnicr5/pinched_sciatic_nerve/
7. X — @WovenDissent, 2026 — anecdotal, positive, elbow tendons — https://x.com/WovenDissent/status/2071612933382037588
8. X — @MuroCrypto, 31 July 2026 — anecdotal, positive, herniated lumbar disc, ran both compounds — https://x.com/MuroCrypto/status/2083184469956059529
9. Reddit r/steroids — u/SwaveyyyD, 16 July 2023 — anecdotal, positive — https://www.reddit.com/r/steroids/comments/150bge2/compounds_healing_compounds_bpc157_tb500/js5hfcw/
10. Reddit r/steroids — u/UnusuallyTarded11, 16 March 2025 — anecdotal, positive, rotator cuff — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4eq0n/
11. Reddit r/steroids — u/MysterMumbles, 17 March 2025 — anecdotal, positive then relapse on stopping — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi9owhr/
12. X — @drmarlonperalta, 4 June 2026 — anecdotal, positive, ten years of low back pain from a herniated disc — https://x.com/drmarlonperalta/status/2062565899714925044
13. X — @AJA_Cortes, 26 May 2024 — anecdotal, positive, L5-S1 flare, writer flags placebo himself — https://x.com/AJA_Cortes/status/1794522474702336108
14. Reddit r/steroids — u/MjolnirCurls, 28 February 2018 — anecdotal, no effect — https://www.reddit.com/r/steroids/comments/7zy7yi/compound_experience_saturday_bpc157/duz790a/
15. Reddit r/backpain — u/ImNotSchema, 19 August 2025 — anecdotal, no effect, ran both compounds — https://www.reddit.com/r/backpain/comments/1mu96us/hlab27_sacroiliitis_on_mri_vs_disc_obliteration/
16. Reddit r/PEDs — u/Itchy_Brain6340, 9 October 2023 — anecdotal, no effect, ran both compounds — https://www.reddit.com/r/PEDs/comments/173pdv4/compounds_to_help_articular_cartilage_fissure_in/
17. X — @prax1s_mm, 30 July 2026 — anecdotal, no effect, third separate attempt, ran both compounds — https://x.com/prax1s_mm/status/2082901582627184835
18. X — @LtCrandog, 30 July 2026 — anecdotal, no effect over ten years of use — https://x.com/LtCrandog/status/2082758463407473109
19. Reddit r/Peptidesource — u/TheAwkwardEmu, 25 July 2026 — anecdotal, no effect at six weeks — https://www.reddit.com/r/Peptidesource/comments/1v6e4g2/need_help_deciding_between_kpv_low_dose/
20. Reddit r/moreplatesmoredates — u/Cr1ms0nSlayer, 8 May 2025 — anecdotal, no effect across two vendors — https://www.reddit.com/r/moreplatesmoredates/comments/1kfp3uf/does_bpc157_increase_recovery_between_workouts/mr860tt/
21. Reddit r/steroids — u/jlthreequarters, 17 March 2025 — anecdotal, no effect, injected near the knee — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi6t9l6/
22. Reddit r/Biohackers — u/Trofas27, 16 June 2026 — anecdotal, effect then loss of effect — https://www.reddit.com/r/Biohackers/comments/1u7ddu1/i_know_some_will_disagreebut_new_batch_of_bpc_157/
23. Reddit r/backpain — u/Miserable_Fan1984, 16 September 2024 — anecdotal, got worse, herniated disc, ran both compounds — https://www.reddit.com/r/backpain/comments/1fi50ar/bpc_157_and_tb_500_for_herniated_disc/
24. Reddit r/PEDs — u/Illustrious_Buy_6545, 18 January 2026 — anecdotal, got worse in an untreated joint — https://www.reddit.com/r/PEDs/comments/1qftcul/bpc157_gone_wrong/
25. Reddit r/Biohackers — u/cityhunterspeee, 20 February 2026 — anecdotal, got worse, vision, ran a blend of both — https://www.reddit.com/r/Biohackers/comments/1ra2m3p/1_month_of_bpc157_tb500_blend_reviewblurry_vision/
26. Reddit r/climbharder — u/WeenieLoft, 22 February 2024 — anecdotal, got worse, swelling at the treated finger — https://www.reddit.com/r/climbharder/comments/1axf2aa/my_experience_case_study_recovering_from_an_a2/
27. Nationwide Peptides — BPC-157 and TB-500 research-chemical listings, prices read 4 August 2026 — https://www.nationwidepeptides.com/products/bpc-157-peptide/
28. FDA — Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks, current as of 22 April 2026 — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
29. STAT News, 23 July 2026 — FDA advisory panel narrowly votes to allow compounding of unapproved peptides — https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/
30. World Anti-Doping Code International Standard — Prohibited List 2026, effective 1 January 2026 — https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
31. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med, 12 April 2026. PMID 41966639 — https://pubmed.ncbi.nlm.nih.gov/41966639/
32. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med, January 2026. PMID 41476424 — https://pubmed.ncbi.nlm.nih.gov/41476424/
33. Reddit r/steroids — u/RGJJBrwn2022, 16 March 2025 — anecdotal, positive, ran both compounds — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4uao6/
34. Reddit r/Biohackers — u/hraww, 9 April 2026 — anecdotal, positive, ran both compounds — https://www.reddit.com/r/Biohackers/comments/1sgf3q0/bpc157_and_tb500_weekly_update/
35. Reddit r/steroids — u/Blahblahblurred, 16 March 2025 — anecdotal, positive, ran both compounds — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4iwuk/


---

# BPC-157 for a herniated disc: what the evidence reaches, and what it does not

slug: bpc-157-herniated-disc · https://miscsubjects.com/a/bpc-157-herniated-disc · tags: peptide, bpc-157, herniated-disc, spine, pairing · updated 2026-08-04T20:48:58.174Z

BPC-157 is a 15-amino-acid chain copied from a sequence found in human stomach juice, sold as a freeze-dried powder for injection or as an oral tablet. Nobody has ever given it to a person with a herniated disc under any kind of controlled test, in any country, and the animal work that exists was done on tendon, muscle, ligament and cut nerve — never on a disc.

That second sentence is the whole shape of the decision, and it is not the same thing as "it does nothing". What follows is the evidence that exists, strongest kind first, the arithmetic for a dose, the legal position on 4 August 2026, and a count of what twenty-four people with a spine problem said happened to them.

The site that publishes this page has a commercial relationship with a seller of this compound. Treat that as a reason to open every source link below rather than a reason to trust the summary.

## Seven in ten of these clear on their own, and that is the number anything has to beat

Before any compound: a meta-analysis pooled 31 studies covering 2,233 people whose herniated discs were managed without surgery. The displaced disc material was reabsorbed in 70.39% of them. The rate ran 87.77% where a fragment had fully broken free, 66.91% for an extrusion, 37.53% for a protrusion, 13.33% for a bulge. Most of the shrinking happened inside the first six months.

[[embed:source:s26]]

And a randomised trial in 283 people with severe leg pain lasting 6 to 12 weeks compared early surgery against continued conservative care. Surgery took the leg pain away faster. At one year, the probability of feeling recovered was 95% in both arms.

[[embed:source:s27]]

Hold those two numbers against everything below. If you start a compound today and feel better in three months, the honest reading is that you are inside the seven-in-ten who were going to improve anyway. Nothing on this page separates you from that group, because no trial has ever been run that could.

[[embed:herniated-disc]]

## Your problem is at least three problems, and a compound can only reach two of them

The first is space. Disc material is sitting where a nerve root needs to be. That is what the scan measures, and the only two things that remove it are your own body digesting the fragment over months and a surgeon cutting it out. No compound in any species has been shown to shrink a herniation.

The second is chemistry. The material that leaked out is not inert. Mice given disc material placed against a nerve root developed lasting leg pain and damage to the nerve cells, with no squeezing involved at all — the inflammatory signal did it.

[[embed:source:s7]]

The inflammatory enzyme measured in human herniated disc material runs 20 to 100,000 times more active than the same enzyme measured from any other source in the literature.

[[embed:source:s8]]

The third is the nerve itself. A root that has been squeezed and chemically burned for weeks has damaged fibres, and that is what produces the numbness, the pins and needles and the weak foot. Nerve fibres regrow at roughly a millimetre a day, which is why that part of the recovery lags the pain by months.

The claim on the table is that this compound reaches the second and third problems and not the first. Read the next two sections deciding whether the animal work supports even that much.

## Nobody has put this compound near a spinal disc, in any species

A systematic review in orthopaedic sports medicine screened 544 articles from 1993 to 2024 and kept 36 studies. Thirty-five were animal or dish work. One was clinical. The tissues were muscle, tendon, ligament and bone.

[[embed:source:s11]]

There is no disc study. Not a rat disc, not a rabbit disc, not a disc in a dish. The tissue that is actually causing your pain has never been exposed to this compound in a published experiment. Every argument for using it on a disc is an argument by analogy from a different tissue, and analogies from tendon to disc are weak: a tendon has a blood supply and a disc, after about age twenty, has almost none.

## What the rats did show, and which of your three problems it lands on

Rat Achilles tendon torn off the bone. Treated animals healed with more strength at the tendon-to-bone join, and the same experiment showed a steroid drug made healing worse while the compound cut that damage back.

[[embed:source:w_59xoi0m3]]

Rat ligament cut through. Better function, better mechanical strength, better tissue on the slide, at both a microgram and a nanogram dose.

[[embed:source:w_ccsq5zep]]

Rat sciatic nerve cut and repaired. The nerve regrew faster and the leg worked better than in untreated animals. This is the single finding on this page that touches nerve tissue, and it is a cut nerve trunk in a rat leg, not a chemically inflamed nerve root in a human spine.

[[embed:source:w_032xvatb]]

Rat spinal cord crushed. Treated animals recovered movement, starting at the tail, and held it out to a year.

[[embed:source:s127]]

Tendon cells in a dish moved to the wound edge faster as the dose went up, and made more of the receptor that growth hormone docks into.

[[embed:source:w_ud0jx8hb]]

[[embed:source:w_y4s15wvm]]

Map that onto your three problems. Space: nothing, in any of it. Chemistry: the nerve and cord work is consistent with the inflamed-nerve part of your pain, in rodents. Structure: the tendon and ligament work is about a tissue you also injured, because a herniation almost always comes with a torn ring and months of guarding, but it is not about the disc.

## The steroid shot you probably already had is the strongest single link here

Most people arrive at this question having already had an epidural or a joint steroid injection, or a course of an anti-inflammatory tablet. Two separate rat studies found a corticosteroid made healing worse in tendon and in muscle, and that this compound reversed that damage. In the muscle study the reversal was described as complete.

[[embed:source:w_gttxaz57]]

And in a rat model of anti-inflammatory drug poisoning, diclofenac at 12.5 mg/kg for three days wrecked the stomach, gut and liver and progressed to brain swelling. The compound blocked that whole cascade, given either by injection or dissolved in the drinking water, at both 10 µg/kg and 10 ng/kg.

[[embed:source:w_odtbasyy]]

Read that carefully. It is a protection finding about the drugs you are already taking, not evidence that the combination heals a disc faster. What it does settle is that the medicine most likely to already be in your system is not, in rats, a documented conflict.

## Fifteen minutes in the blood, which is what decides the schedule

The only measurements of what a body does with this compound come from rats and beagles. Average time to clear half of it: 15.2 minutes. Into a vein in dogs: 5.27 minutes. Peak in the blood three minutes after an injection into muscle. The fraction reaching the blood after an injection into muscle was 14–19% in rats and 45–51% in dogs.

[[embed:source:w_n7ahbrni]]

Two things follow for a daily plan. A compound gone that fast is not working by holding a level in your blood, so splitting a daily dose beats taking it all at once, and a once-weekly schedule has no argument behind it. None of these numbers has ever been measured in a person.

## Turning a 10 mg vial into a number of marks on a barrel

The powder arrives sealed. You add bacteriostatic water — sterile water with 0.9% benzyl alcohol in it, which is the preservative that lets you put a needle back into the same vial for weeks. Plain sterile water dissolves it fine but makes the vial a one-time proposition.

The measuring device is a U-100 insulin syringe: 100 marks to a millilitre, so one mark is 0.01 mL. Two lines give you every conversion.

- Micrograms per mL = micrograms in the vial ÷ mL of water added.
- Micrograms per mark = that number ÷ 100.

A 10 mg vial holds 10,000 mcg. Add 3 mL and you have 3,333 mcg/mL, which is 33.3 mcg per mark. A 250 mcg dose is 250 ÷ 33.3 = 7.5 marks.

| Vial | Water added | Strength | Mcg per mark | Marks for 250 mcg | Marks for 500 mcg | Days at 500 mcg split into two |
|---|---|---|---|---|---|---|
| 5 mg | 2.0 mL | 2,500 mcg/mL | 25 | 10 | 20 | 10 |
| 5 mg | 2.5 mL | 2,000 mcg/mL | 20 | 12.5 | 25 | 10 |
| 10 mg | 2.0 mL | 5,000 mcg/mL | 50 | 5 | 10 | 20 |
| 10 mg | 3.0 mL | 3,333 mcg/mL | 33.3 | 7.5 | 15 | 20 |
| 10 mg | 5.0 mL | 2,000 mcg/mL | 20 | 12.5 | 25 | 20 |

Adding more water does not add or remove peptide. It only changes how many marks carry a given dose. Below about five marks per dose, misreading the barrel starts to matter more than the dose does, which is the argument for putting 3 mL rather than 2 mL into a 10 mg vial.

Once mixed and kept at 2–8 °C, the vial has about four weeks in it, and that limit comes from the preservative rather than the peptide. Do not shake it and do not freeze it after mixing — both tear the peptide chains apart and make them clump, and clumping is exactly the trigger FDA named for the immune system reacting to an injected peptide.

## Where the needle goes was never answered by the animal work

Every rat study injected either into the belly cavity or into a muscle far from the injury, and the healing still showed up at the wound. Nobody ran the experiment that compares injecting at the site against injecting anywhere else. So the widespread instruction to inject next to your spine rests on nothing published, and the people in the counted record below who got results injecting into a thigh or a glute are evidence against it mattering much.

## Where it stands legally, checked 4 August 2026

FDA placed the compound in the bulk-substance bucket flagged for significant safety risk, which is what stopped compounding pharmacies from making it.

[[embed:source:w_ghpbaz64]]

On 23 July 2026 the agency's own Pharmacy Compounding Advisory Committee voted against that position: eight yes, six no, one abstention. Reporting on the meeting noted that most of the yes votes came from members with peptide-industry ties. An advisory vote changes no rule by itself.

[[embed:source:w_38qd7eam]]

[[embed:source:s129]]

[[embed:source:w_lkfuwkh8]]

It is on the 2026 World Anti-Doping Agency prohibited list, in the class covering substances with no approval for human use, banned at all times in and out of competition.

[[embed:source:w_u19qrezt]]

[[embed:source:w_af5ht9pr]]

The only registered trial with a person and an injury in it is a Phase 2 study in acute hamstring strain, which is muscle, not disc, and had not reported when this page was checked.

[[embed:source:s6]]

The one safety measurement in people is a pilot infusion of up to 20 mg into a vein in two healthy adults, with no adverse effects recorded. Two people is a safety signal about a single infusion, not about eight weeks of daily injection.

[[embed:source:s3]]

## Twenty-four people with a spine problem said what happened, and here is the count

Method: searched old.reddit.com for "bpc 157 herniated disc", "bpc 157 sciatica" and "bpc157 disc bulge", read 18 threads in full, pulled 113 comments that name the compound, and kept the ones where a named account described their own lumbar or cervical spine problem and what happened. Twenty-four had a stated outcome. Two more had started too recently to count. That is the denominator; everything else in those threads was sourcing questions, dosing questions and injuries in other body parts.

**Sixteen said it helped.** The most detailed is an L5/S1 herniation treated with about 600 mcg a day for two and a half months, injected into the upper glute rather than the back, with no physical therapy at all — pain-free at the one-year mark, with the caveat added later that a nerve sensation in the leg came back after returning to Muay Thai, and "spinal discs require a good amount of time to fully heal."

Speed varied wildly. One person with L3–L5 bulging discs on 250 mcg of the compound plus 250 mcg of TB-500 twice a day wrote on day five that "the chronic pain is melting away, as of day three." Another, six years into an L4/L5 herniation with leg pain, reported at four days that a four-hour drive produced no pain for the first time. At the other end, one person with seven herniated discs wrote at 32 days that they had not felt this much relief in years, and another took eighteen months to recover without surgery while also doing physical therapy and taking collagen.

Almost every one of the sixteen was doing something else at the same time. TB-500 in most of them, physical therapy in several, a steroid injection in one, gabapentin in one, red-light therapy in one, weight loss in one. Three were reporting after surgery — one after a microdiscectomy that left them with a dropped foot, who wrote that five weeks of the pair "healed me". None of the sixteen is a clean read on this compound alone.

**Two said it worked and then stopped working when they stopped taking it.** One: six weeks of it "lowered the inflammation enough for life to be manageable. I was able to lift weights and stuff again. A week after running out of BPC-157 the pain came back completely. If not worse than before." The other finished a twelve-week run and found the pain returned, though not to where it had been.

That pattern is worth more attention than any of the enthusiastic reports, because it is what you would expect from something quieting inflammation around an irritated nerve rather than repairing anything. Relief that ends with the injections is relief, not repair.

**Five said nothing happened.** One with an L5/S1 herniation since age eighteen injected into their own back for three months and "couldn't tell you that it made any difference." One with an L3/4 bulge and an L5/S1 herniation ran the compound at 250 mcg a day with 5 mg of TB-500 a week for six weeks and had "zero noticeable difference in back pain over 6 weeks" — a dose at the bottom of the common range, which is the obvious objection to that one. One with two bulging discs tried it on several separate occasions and it did not help. One never injected anywhere near the back and said it did not do much. One said they noticed nothing and wondered aloud whether they had run it long enough.

**One got worse, in a specific and checkable way.** Two weeks in, their prescription pain medication stopped working. They stopped the compound and the medication started working again within 24 to 36 hours. That is a reported interaction with an opioid painkiller, from one person, uncontrolled, and it is the only harm report in the set that is about the spine problem rather than about the compound in general.

One further account belongs here and is not in the count. A person with multiple herniated discs from a car crash, with a graduate degree in kinesiology, who had taken this compound for other injuries, attributed her own recovery to a different peptide entirely and argued that this one "primarily targets soft tissue and ligament repair, which may be less directly effective in regenerating the disc structure itself." That is the same objection the missing disc study raises, made by someone who used the compound and did not credit it.

**What the count settles and what it does not.** Sixteen out of twenty-four is a high hit rate, and it is also exactly what you would get from a condition where seven in ten people improve without doing anything, in a population that self-selected by buying an expensive compound and posting about it. Nobody posts a thread called "I bought it and nothing happened", which is why the five negatives matter more than their share suggests. The two relapse reports are the most informative thing in the whole set, and no trial exists that would resolve them.

## What would have to change for any of this to be settled

One rat study putting the compound near a damaged disc would tell you whether the analogy from tendon holds. One trial randomising people with a confirmed extrusion to the compound or a placebo, measuring leg pain at six weeks and the fragment on a scan at six months, would separate it from the 70% who resorb anyway. Neither exists, neither is registered, and the only trial running is in hamstrings.

[[embed:bpc-157]]

[[embed:ara-290-herniated-disc]]

[[embed:tb-500-herniated-disc]]

[[embed:wolverine-stack]]


## Sources

1. Incidence of Spontaneous Resorption of Lumbar Disc Herniation: A Meta-analysis (Clin Spine Surg 2024, PMID 37559207) — https://pubmed.ncbi.nlm.nih.gov/37559207/
2. Surgery versus prolonged conservative treatment for sciatica (NEJM 2007, PMID 17538084) — https://pubmed.ncbi.nlm.nih.gov/17538084/
3. TNF-alpha in the nucleus pulposus mediates radicular pain in mice — https://pubmed.ncbi.nlm.nih.gov/18670336/
4. High levels of inflammatory phospholipase A2 activity in lumbar disc herniations — https://pubmed.ncbi.nlm.nih.gov/2218714/
5. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — https://pubmed.ncbi.nlm.nih.gov/40756949/
6. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation — https://pubmed.ncbi.nlm.nih.gov/16583442/
7. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat — https://pubmed.ncbi.nlm.nih.gov/20225319/
8. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury — https://pubmed.ncbi.nlm.nih.gov/19903499/
9. BPC 157 improves the healing course of spinal cord injury and leads to functional recovery in rats — https://pmc.ncbi.nlm.nih.gov/articles/PMC6604284/
10. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration — https://pubmed.ncbi.nlm.nih.gov/21030672/
11. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts — https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/
12. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application — https://pubmed.ncbi.nlm.nih.gov/20190676/
13. Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions — https://pubmed.ncbi.nlm.nih.gov/21295044/
14. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs — https://pmc.ncbi.nlm.nih.gov/articles/PMC9794587/
15. Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act — https://www.fda.gov/media/94155/download
16. July 23-24, 2026: meeting of the Pharmacy Compounding Advisory Committee — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
17. An FDA Committee Just Voted in Favor of Peptides-Despite the Agency's Opposition (TIME) — https://time.com/article/2026/07/23/fda-committee-peptides/
18. FDA advisory panel narrowly votes to allow compounding of unapproved peptides — https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/
19. World Anti-Doping Code International Standard: Prohibited List 2026 — https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
20. BPC-157: experimental peptide creates risk for athletes — https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/
21. BPC 157 for Acute Hamstring Muscle Strain Repair — https://clinicaltrials.gov/study/NCT07437547
22. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study — https://pubmed.ncbi.nlm.nih.gov/40131143/
23. Healing a herniated disc and severe sciatica pain (r/Sciatica) — https://old.reddit.com/r/Sciatica/comments/1bu215m/healing_a_herniated_disc_and_severe_sciatica_pain/
24. Peptides for lower back pain recovery (r/backpain) — https://old.reddit.com/r/backpain/comments/14iol96/peptides_for_lower_back_pain_recovery/
25. I took BPC-157 for 6 weeks after struggling with disc herniation (r/bpc_157) — https://old.reddit.com/r/bpc_157/comments/1gjuas9/i_have_sciatica_from_a_bulged_disc_and_it_has/no45zaf/
26. I tried both TB-500/BPC-157 together for L3/4 bulge and L5/S1 herniation (r/Biohacking) — https://old.reddit.com/r/Biohacking/comments/1rj45d2/bpc157_for_lower_back_pain/o8aqhiq/
27. 43 yo, L5/S1 herniated disc since I was 18 (r/Biohackers) — https://old.reddit.com/r/Biohackers/comments/1fvf89s/been_struggling_with_2x_herniated_discs_for_over/lq8f8jp/
28. BPC-157 blunted a prescription painkiller (r/Biohacking) — https://old.reddit.com/r/Biohacking/comments/1rj45d2/bpc157_for_lower_back_pain/
29. Multiple herniated discs after a rear-end crash (r/bpc_157) — https://old.reddit.com/r/bpc_157/comments/1foo6q0/bpc_157_to_aid_herniated_discs/losyqg1/


---

# BPC-157 vs NSAIDs: Repair or Suppress?

slug: bpc-157-vs-nsaids · https://miscsubjects.com/a/bpc-157-vs-nsaids · tags: bpc-157, nsaids, tendon, regeneration, disc · updated 2026-08-04T20:45:47.628Z

Say the asymmetry out loud before anything else, because most pages comparing these two hide it.

**Ibuprofen has been tested in people, at scale, and it works.** A Cochrane overview pulled together 39 systematic reviews covering roughly 460 randomised trials and about 50,000 participants, all measuring one thing: how many people get at least half their pain taken away. Ibuprofen 400 mg came out at a number-needed-to-treat of 2.5 — treat five people, two get at least 50% pain relief who would not have got it from a dummy pill. Fast-acting ibuprofen 200 mg: 2.1. Ibuprofen 200 mg with paracetamol 500 mg: 1.6, one of the best numbers in the entire table.

[[embed:source:s23]]

**BPC-157 has never completed a randomised controlled trial in a human being for any injury.** Not for tendon, not for muscle, not for a disc, not for a joint. The evidence is rats, a small number of early-phase human safety studies on other conditions, and a large volume of self-reported experience.

[[embed:bpc-157]]

That is the honest starting position and it does not favour the peptide. If your only question is "will this reduce my pain in the next four hours," the answer is the drug with 50,000 participants behind it, and no amount of mechanism argument changes that.

Now the two things that make this a real question rather than a rout.

## For back pain specifically, the drug's own trials are unimpressive

The 50,000-participant number comes from post-surgical pain. Back pain is a different question and it has its own trials, and they are far less flattering.

**Acute low back pain.** Cochrane pooled 32 trials, 5,356 participants. Against placebo, anti-inflammatories reduced pain by **7.29 points on a 0–100 scale** (95% CI −10.98 to −3.61), moderate-quality evidence. Disability improved by 2.02 points on a 0–24 scale, high-quality evidence. The reviewers' own summary of that magnitude: "small and probably not clinically relevant." No difference between COX-2-selective and older ones. Almost half the studies were industry-funded.

[[embed:source:s21]]

**Chronic low back pain.** Cochrane, 13 trials. Against placebo, **3.30 points on the same 0–100 scale** (95% CI −5.33 to −1.27), low-quality evidence. Disability, 0.85 points on a 0–24 scale. And this line, which deserves to be read twice: when the reviewers restricted the analysis to trials at low risk of bias, the difference between the drug and placebo got *smaller*.

[[embed:source:s22]]

Set those numbers beside the one intervention with a genuinely large effect for the same condition: structured exercise, pooled across 249 randomised trials, produced a **15.2-point** pain reduction, which cleared the reviewers' pre-set threshold for a clinically important difference.

[[embed:source:s24]]

So the honest ranking for a back, on human trial evidence, is: exercise 15.2 points, anti-inflammatories 7.3 points for acute and 3.3 for chronic, BPC-157 untested. The drug beats the peptide because the peptide has nothing. It loses badly to walking and lifting.

## What each one actually does to the tissue

An anti-inflammatory blocks an enzyme called COX-2. COX-2 makes prostaglandins. Prostaglandins are what make an injury swell, throb and hurt. Block the enzyme, lose the prostaglandins, lose the pain. That is the whole drug.

The complication is that prostaglandins are not only a pain signal. They are also the opening instruction of tissue repair — the message that recruits repair cells to a damaged site and starts the rebuilding. One molecule, two jobs. The drug cannot separate them.

BPC-157 runs the opposite way. It is a short chain of fifteen amino acids based on a sequence found in human stomach juice, and in animals it raises VEGF, the signal that grows new blood vessels into damaged tissue, and drives connective-tissue cells to migrate into and repair an injury. It has no pain-blocking action of its own worth speaking of.

One suppresses the signal. The other is studied for accelerating what the signal is calling for. That is the actual axis of this comparison, and neither side of it is automatically the right answer — it depends entirely on what you are trying to buy.

## The case against months of anti-inflammatories is specific, numbered, and not about healing

Most arguments against these drugs are vague and moralising. The real case is none of those things. It is four separate, measured harms, three of which are not in serious dispute.

### The stomach

The largest analysis of individual patient data — 280 trials against placebo covering 124,513 participants, plus 474 head-to-head trials covering 229,296 — put numbers on it by drug. Upper gastrointestinal complications, meaning a perforation, obstruction or bleed:

| Drug | Increase in upper gut complications vs placebo |
|---|---|
| Naproxen | 4.22× |
| Ibuprofen | 3.97× |
| Diclofenac | 1.89× |
| COX-2-selective drugs (coxibs) | 1.81× |

[[embed:source:s18]]

Note what that table does to the popular story. Naproxen, the one usually recommended as the heart-safe choice, has the *worst* gut number in the set. There is no drug in that column that is free.

The head-to-head randomised trial confirms the direction. PRECISION randomised 24,081 patients with arthritis and raised heart risk to celecoxib, ibuprofen or naproxen for a mean of 20 months. Gastrointestinal events were significantly lower with celecoxib than with either naproxen (p=0.01) or ibuprofen (p=0.002).

[[embed:source:s19]]

### The heart

From the same 124,513-participant analysis:

| Drug | Major vascular events | Major coronary events |
|---|---|---|
| Coxibs | 1.37× | 1.76× |
| Diclofenac | 1.41× | 1.70× |
| Ibuprofen | 1.44× (not significant) | 2.22× |
| Naproxen | 0.93× (no increase) | — |

**Heart failure risk was roughly doubled by all of them.** In absolute terms: for every 1,000 people taking a coxib or diclofenac for a year, three extra major vascular events, one of them fatal.

[[embed:source:s18]]

That is the honest trade-off between the two tables. Naproxen is the kindest to your heart and the harshest on your stomach. Celecoxib is the reverse. There is no free option, and PRECISION found celecoxib was not worse than the other two on heart outcomes at moderate doses, which softened but did not erase the coxib concern.

[[embed:source:s19]]

### The kidneys

Forty studies covering 1,757,118 participants. Long-term use raised the odds of developing or worsening chronic kidney disease: pooled odds ratio 1.24, pooled hazard ratio 1.50. In people who already had kidney disease, the hazard ratio was 1.67.

[[embed:source:s20]]

In PRECISION, kidney events were significantly lower with celecoxib than with ibuprofen (p=0.004).

[[embed:source:s19]]

### The report pile at the regulator, and exactly what it is not

FDA's public adverse event system holds reports sent in voluntarily by patients, doctors and manufacturers. Queried on 4 August 2026, it holds **283,544 reports naming ibuprofen** and **165,063 naming naproxen**.

Say what those numbers are before reading them. They are counts of reports, not counts of people harmed. There is no denominator anywhere in the system — nobody knows how many people took either drug and reported nothing, and that missing number is the one an incidence rate would need. A report is not a finding that the drug caused the event. The same event can arrive more than once. Reporting rises when a drug is in the news. Nothing in this table is a rate, and it cannot be turned into one.

| Reported event | Reports naming ibuprofen | Reports naming naproxen |
|---|---|---|
| Acute kidney injury | 7,141 | 3,145 |
| Kidney failure | 4,216 | 2,562 |
| Bleeding in the gut | 2,689 | 1,486 |
| Heart attack | 1,781 | 1,770 |
| Stomach ulcer | 1,394 | 867 |
| Black stool from a gut bleed | 1,208 | 478 |
| Heart failure | 634 | 305 |
| Bleeding from the stomach lining | 622 | 489 |
| Ulcer in the first part of the small intestine | 614 | 359 |

[[embed:source:s42]]

Two things are worth taking from it. The kidney rows sit above the gut rows for both drugs, which is the opposite of the ordering most people carry in their heads, and it lines up with the direction of the 1,757,118-participant kidney analysis rather than contradicting it. And the single most reported term for both drugs is not a harm at all: **"drug ineffective" — 27,383 times for ibuprofen and 22,584 for naproxen.** Set that beside the Cochrane back-pain numbers at the top of this page and it is the same finding arriving from the other end of the evidence pyramid.

The controlled trials above give you rates. This gives you the shape of what lands when something goes wrong. Use it for the second and never for the first.

### Tendon and soft-tissue healing — the one that is genuinely contested

This is the argument most often made and least often made carefully. Here is what the evidence supports and where it stops.

**In animals it is consistent and specific.** In a rotator cuff repair model, both an older anti-inflammatory (indomethacin) and a COX-2-selective one (celecoxib) produced significantly weaker tendon-to-bone healing than untreated controls, out to eight weeks.

[[embed:source:s1]]

**The timing pattern is the strongest part of the case.** Give ibuprofen during the early repair window and tendon healing is measurably worse; give the same drug later and the effect fades. That is exactly the pattern you would predict if the drug is interrupting the initial repair instruction rather than merely masking pain.

[[embed:source:s3]]

**Bone shows it too.** Pooled animal data show these drugs measurably reduce the mechanical strength of healing fractures.

[[embed:source:s6]]

**The mechanism is not a coincidence.** Knock out COX-2 in mice and fractures heal badly. Restore the downstream prostaglandin signal and the healing is rescued. The enzyme the drug exists to block is the same enzyme repair runs on.

[[embed:source:s8]]

**It reaches human repair cells.** In a human study, infusing an anti-inflammatory locally during exercise abolished the normal rise in muscle satellite cells — the stem cells that rebuild muscle after loading.

[[embed:source:s7]]

**And now the counter-evidence, which is real.** A meta-analysis of human fracture outcomes that adjusted for confounders found **no significant increase in fracture non-union** among people taking these drugs.

[[embed:source:s5]]

**There is even a species-level reason it might not translate.** Human skeletal stem cells were directly compared with rodent ones and turned out to be substantially less dependent on COX-2 for their function.

[[embed:source:s4]]

So the fair verdict, stated as a rate rather than a mood: **animal healing impairment is consistently reproduced; human cellular repair signals are measurably blunted; human clinical healing outcomes show no proven harm.** Anyone claiming these drugs are proven to wreck human healing is overstating. Anyone claiming the concern is invented is ignoring the timing data and the knockout mice.

## Why this argument gets sharper when the injury is a disc

A herniated disc is the one case where the healing question is not theoretical, because the mechanism that removes a herniation *is* an inflammatory mechanism.

Displaced disc material meets blood supply and immune cells for the first time. Immune cells digest it, new blood vessels grow in to supply the operation, and about 70% of herniations reabsorb on their own within roughly six months.

[[embed:herniated-disc]]

Suppress that inflammation continuously and you are working against the clearance. This is not purely inference: corticosteroids inhibited resorption in preclinical work, and a clinical series that deliberately withheld anti-inflammatory drugs reported resorption in every patient.

[[embed:source:s17]]

That evidence is a case series, not a randomised trial, and it should be weighted as such. But it points the same direction as the tendon timing data, and it is the reason "a few days for a flare" and "eight months of daily tablets" are different decisions rather than different doses of the same decision.

The slower wear process behind many of these discs is a separate question with its own numbers, and it changes what a long course of anything is being asked to do:

[[embed:degenerative-disc-disease]]

## What BPC-157 actually has, listed without inflation

**In animals, the tendon results are the strongest thing it has.** A transected rat Achilles tendon treated with BPC-157 came back with greater load-to-failure and better collagen organisation than controls.

[[embed:source:s10]]

**The cellular behaviour matches.** Tendon cells showed better outgrowth, survival and migration — the three behaviours that define active repair rather than scarring over.

[[embed:source:s11]]

**And the mechanism is the mirror image of the drug's.** BPC-157 raises VEGF and drives new blood vessel growth into healing muscle and tendon — the same vascular pathway that COX-2 blockade suppresses.

[[embed:source:s12]]

**It protects against the drug's own gut damage, in rats.** Given alongside diclofenac, BPC-157 counteracted the gastrointestinal, liver and brain lesions the drug caused.

[[embed:source:s13]]

**The same protection held when adjuvant arthritis and drug-induced gut lesions were put on the animal together.**

[[embed:source:s14]]

**What none of that is:** a human result. Every item above is a rodent. There is no completed randomised controlled trial of BPC-157 in a human injury, no dose established for a human tendon, and no study of any kind against a human disc.

[[embed:tb-500]]

[[embed:ara-290]]

[[embed:what-are-peptides-herniated-disc]]

## Seven people on long-term anti-inflammatories, counted

**Seven first-person accounts from X, counted.** **Four of the seven reported a harm. One was warned off by a doctor before anything went wrong. One reported no problems over more than ten years. One is worried and getting tested, with no result back yet.**

Read this panel knowing exactly what is wrong with it: people post about the ulcer that sent them to hospital, not about the uneventful decade. The harm fraction here is not the population rate — the population rate is in the tables above, and it is a 4× relative increase on a small absolute base, not four in seven. This panel tells you what the harm looks like when it lands, not how often it lands.

**Reported a harm — 4 of 7.**

Kidney filtration flagged on bloodwork after years of six tablets a day:

[[embed:source:s25]]

A stomach bleed that lasted a year, and twelve years of avoiding the whole drug class afterwards:

[[embed:source:s26]]

Five tablets a day for five years for back pain, and a stomach that can no longer tolerate the drug at all:

[[embed:source:s27]]

An ulcer, black stool, and an emergency room:

[[embed:source:s28]]

**Warned off, no harm reported yet — 1 of 7.** Nearly two years of naproxen with a stomach-protecting drug alongside it, then a new doctor capping it at six months:

[[embed:source:s29]]

**No problems — 1 of 7.** Over ten years of use, including long continuous stretches, and no reported issue:

[[embed:source:s30]]

**Worried, no result yet — 1 of 7.** Years of heavy use, now getting kidney and liver function tested:

[[embed:source:s31]]

## Ten people on BPC-157, counted

**Ten first-person accounts from X**, all self-reported, none verified, none from a trial. **Six said it helped. One said it helped and raised the possibility of placebo himself. Two said it did not work. One reported no outcome either way. Nobody reported a serious harm, and the only physical complaint in the set was at an injection site.**

Two of the six positive accounts carry either a supplier link or a follow-me pitch attached to the post. That is not proof they are false, but it is a selection problem you should hold in mind while reading them.

**Said it helped — 6 of 10.**

A dried-out lower disc plus a year-old biceps tendon problem, six weeks of BPC-157 and TB-500 — tendon and shoulder resolved, disc improved but explicitly still needing physiotherapy:

[[embed:source:s32]]

Elbow tendon pain of months' standing, injected locally at the site:

[[embed:source:s33]]

A two-and-a-half-year knee injury the poster says nothing else had fixed:

[[embed:source:s34]]

Shoulder and joint pain on the BPC-157 plus TB-500 combination — note this post also links a supplier:

[[embed:source:s35]]

A rotator cuff for which surgery had been recommended, two eight-week cycles, surgery avoided — note this post ends in a follow-me pitch:

[[embed:source:s36]]

Two months, rotator cuff quiet during training, and heartburn gone as a side effect:

[[embed:source:s37]]

**Helped, but he flagged placebo himself — 1 of 10.** This is the most intellectually honest account in the set, and it is worth more than the enthusiastic ones:

[[embed:source:s38]]

**Said it did not work — 2 of 10.**

Ten years of on-and-off use and a flat verdict, including new tendon pain appearing while on it:

[[embed:source:s39]]

Eight weeks for a shoulder, judged not a success — with an interesting detail: stomach problems he had stopped noticing came back two weeks after stopping, which is the one place his account supports the gut-protective animal data even while rejecting the injury claim:

[[embed:source:s40]]

**No outcome reported — 1 of 10.** An injection-site problem from using too large a needle.

[[embed:source:s41]]

**What ten accounts can and cannot establish.** They cannot establish that it works — there is no control group, no blinding, no independent measurement, and a heavy bias toward people who bought the thing and want it to have worked. What they do establish, honestly: the reported experience is not uniformly positive, two of ten users describe no benefit at all, one of the enthusiasts volunteered placebo as an explanation unprompted, and nobody in this set reported a serious adverse event. Hold that against the 50,000-participant table at the top of this page and the size of the gap is the point.

## What is legal, which is a separate question from what works

**BPC-157 is not an approved drug anywhere.** Its regulatory position has moved recently, so the specific dates matter more than the summary. FDA placed it in Category 2 of the 503A bulk substances list in September 2023, barring pharmacy compounding. It was off all three categories by the 14 May 2026 revision after the nominations were withdrawn. In July 2026 FDA's own briefing document recommended against adding it; on 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8–6 with one abstention to recommend adding it anyway, against FDA staff. It is not on the 503B outsourcing-facility list either.

**It is prohibited in sport at all times.** WADA's 2026 Prohibited List names BPC-157 explicitly under S0, non-approved substances — in and out of competition, not only on competition day. The US Department of Defense lists it on its Prohibited Dietary Supplement Ingredients List and states plainly that it is not a dietary ingredient but an unapproved drug, at any route.

**What it is sold as:** research chemical, research use only. That is a shipping label, not a legal category granting you permission to use it.

[[embed:bpc-157]]

**Ibuprofen and naproxen are over-the-counter medicines** with approved labels, approved dose ceilings, and pharmacist advice attached. That difference is not a footnote — it is the reason one of them has 50,000 participants of evidence behind it and the other does not.

## The decision table

| Your situation | What the evidence supports | What the evidence does not support | Legal position |
|---|---|---|---|
| Acute pain in the first few days, any injury | A short course of an anti-inflammatory. NNT 2.5 for ibuprofen 400 mg on at least 50% pain relief | That it speeds your healing, or that avoiding it makes you heal better | Over the counter |
| Acute back pain specifically | The same short course, with realistic expectations — 7.3 points on a 0–100 scale, which the reviewers called probably not clinically relevant | That it will do much. Movement outperforms it by roughly double | Over the counter |
| Chronic back pain, months in | Exercise. 15.2 points across 249 trials, against 3.3 points for the drug | Daily long-term anti-inflammatories as the plan. The effect shrinks in the least-biased trials and the harm accumulates | Over the counter, but this is the use with the harm tables attached |
| A herniated disc actively reabsorbing | Short courses to enable movement | Continuous suppression for months. Steroids inhibited resorption in preclinical work; one series avoiding these drugs saw resorption in every patient | Over the counter |
| You already have stomach disease or a bleed history | Avoiding the older drugs. Coxibs 1.81× vs ibuprofen 3.97× and naproxen 4.22× for upper gut complications | That any of them is gut-neutral | Prescription for coxibs in most places |
| You have heart disease or heart failure | Caution across the whole class. Heart failure risk roughly doubled by all of them; naproxen alone did not raise major vascular events | That the choice of drug removes the risk | Over the counter, which does not mean low-risk here |
| You have kidney disease | Avoiding long-term use. Hazard ratio 1.67 for progression in people who already have it | That short courses carry the same risk as chronic use | Over the counter |
| Tendon or soft-tissue injury where healing is the goal | Load management, progressive rehabilitation, and using pain relief sparingly in the first repair window | Either extreme. Animal harm is consistent; human non-union data shows none | Over the counter |
| You are considering BPC-157 for an injury | Nothing, in humans. Animal tendon repair is real and consistent; that is the entire honest case | Any human dose, any human timeline, any disc claim, any comparison of its effect size to the drug's | Not approved anywhere. Banned in sport at all times. Prohibited for US service members |
| You are a competing athlete | Whatever is on your sport's permitted list | Using BPC-157 under any framing, including "research use only" | WADA S0, strict liability, in and out of competition |

## The one-line version of each side

**For the drug:** it demonstrably relieves pain in humans at scale, it is legal, it is cheap, and the healing concern is unproven in human outcomes. Its costs are measured, drug-specific, and rise with duration rather than dose alone.

**For the peptide:** it has a coherent repair mechanism, consistent animal tendon results, and animal evidence that it protects the gut lining the drug damages. It has no human trial for any injury, no established dose, no legal approval, and a user-report base with two in ten reporting nothing at all.

Those two paragraphs are not equivalent and this page has not tried to make them equivalent. One is a medicine with a known effect size and a known bill. The other is an interesting hypothesis being taken by a lot of people ahead of its evidence.

*This page compares the state of the evidence. It is not medical advice and not a dosing recommendation. Do not stop a prescribed medicine on the basis of a web page. BPC-157 is sold for research use only, is not approved for human use in any jurisdiction, and is prohibited in sport at all times.*


## Sources

1. Indomethacin and celecoxib impair rotator cuff tendon-to-bone healing — https://pubmed.ncbi.nlm.nih.gov/16210573/
2. NSAID therapy effects on healing of bone, tendon, and the enthesis — https://pmc.ncbi.nlm.nih.gov/articles/PMC3764618/
3. The detrimental effects of systemic Ibuprofen delivery on tendon healing are time-dependent — https://pubmed.ncbi.nlm.nih.gov/23982408/
4. Cross-species comparisons reveal resistance of human skeletal stem cells to inhibition by NSAIDs — https://pmc.ncbi.nlm.nih.gov/articles/PMC9454294/
5. Do NSAIDs affect bone healing rate, delay union, or cause non-union: an updated systematic review and meta-analysis — https://pmc.ncbi.nlm.nih.gov/articles/PMC11420001/
6. NSAIDs and bone healing in animal models - a systematic review and meta-analysis — https://pmc.ncbi.nlm.nih.gov/articles/PMC8268344/
7. Local NSAID infusion inhibits satellite cell proliferation in human skeletal muscle after eccentric exercise — https://pubmed.ncbi.nlm.nih.gov/19713429/
8. Rescue of impaired fracture healing in COX-2-/- mice via activation of prostaglandin E2 receptor subtype 4 — https://pubmed.ncbi.nlm.nih.gov/19628768/
9. Reduced COX-2 Expression in Aged Mice Is Associated With Impaired Fracture Healing — https://pmc.ncbi.nlm.nih.gov/articles/PMC3276605/
10. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and stimulates tendocyte growth in vitro — https://pubmed.ncbi.nlm.nih.gov/14554208/
11. The promoting effect of BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration — https://pubmed.ncbi.nlm.nih.gov/21030672/
12. Modulatory effect of BPC 157 on angiogenesis in muscle and tendon healing — https://pubmed.ncbi.nlm.nih.gov/20388964/
13. BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced GI, liver, and encephalopathy lesions — https://pubmed.ncbi.nlm.nih.gov/21295044/
14. BPC 157 positively affects both NSAID-induced gastrointestinal lesions and adjuvant arthritis in rats — https://pubmed.ncbi.nlm.nih.gov/9403784/
15. NSAIDs and Risk of Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis — https://pmc.ncbi.nlm.nih.gov/articles/PMC12746519/
16. Management of Acute Pain From Non-Low Back Musculoskeletal Injuries: ACP/AAFP Clinical Guideline — https://pubmed.ncbi.nlm.nih.gov/32805126/
17. Lumbar Disc Herniation Resorption: When and How Does It Occur? — https://pmc.ncbi.nlm.nih.gov/articles/PMC12890389/
18. Vascular and upper gastrointestinal effects of NSAIDs: meta-analyses of individual participant data from randomised trials (Lancet 2013, PMID 23726390) — https://pubmed.ncbi.nlm.nih.gov/23726390/
19. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis — PRECISION (NEJM 2016, PMID 27959716) — https://pubmed.ncbi.nlm.nih.gov/27959716/
20. NSAIDs: what is the actual risk of chronic kidney disease? A systematic review and meta-analysis (Rom J Intern Med 2025, PMID 39412516) — https://pubmed.ncbi.nlm.nih.gov/39412516/
21. Non-steroidal anti-inflammatory drugs for acute low back pain (Cochrane 2020, PMID 32297973) — https://pubmed.ncbi.nlm.nih.gov/32297973/
22. Non-steroidal anti-inflammatory drugs for chronic low back pain (Cochrane 2016, PMID 26863524) — https://pubmed.ncbi.nlm.nih.gov/26863524/
23. Single dose oral analgesics for acute postoperative pain in adults — an overview of Cochrane reviews (Cochrane 2015, PMID 26414123) — https://pubmed.ncbi.nlm.nih.gov/26414123/
24. Exercise therapy for chronic low back pain (Cochrane 2021, PMID 34580864) — https://pubmed.ncbi.nlm.nih.gov/34580864/
25. Six ibuprofen a day for years, kidney filtration flagged on bloodwork (anecdotal) — https://x.com/rjust1421/status/2079732817420816700
26. A stomach bleed that lasted a year, then twelve years avoiding the whole drug class (anecdotal) — https://x.com/TheFengHunter/status/2065052345642205232
27. Five ibuprofen a day for five years for back pain, stomach no longer tolerates it (anecdotal) — https://x.com/jbf789/status/2060150691117605310
28. Ulcer, black stool, emergency room (anecdotal) — https://x.com/DadStrayer/status/2051426299843870966
29. Two years of naproxen for spinal pain, then a six-month cap (anecdotal) — https://x.com/BraisbyI/status/2076624300556112226
30. Over ten years of use, no reported problems (anecdotal) — https://x.com/meetjeo/status/2036117578112766127
31. Years of heavy use, kidney and liver tests pending (anecdotal) — https://x.com/BamaDarling/status/2080126143349346337
32. A dried-out lower disc plus a year-old biceps tendon problem, six weeks of BPC-157 and TB-500 (anecdotal) — https://x.com/MuroCrypto/status/2083184469956059529
33. Elbow tendon pain of months, 2 mg injected locally each day (anecdotal) — https://x.com/Compound_Cowboi/status/2083353093878448335
34. A two-and-a-half-year knee injury the poster says nothing else fixed (anecdotal) — https://x.com/raymondAjenkins/status/2084117597361189075
35. Lifelong shoulder and joint pain on the BPC-157 plus TB-500 combination — post links a supplier (anecdotal) — https://x.com/BenWolf1425771/status/2083968934064316770
36. Rotator cuff surgery recommended, two eight-week cycles, surgery avoided — post ends in a follow-me pitch (anecdotal) — https://x.com/michaelo_x/status/2072480753938751554
37. Two months, rotator cuff quiet during training, heartburn gone (anecdotal) — https://x.com/Shift_leader06/status/2071665450971181146
38. A disc flare that resolved in seven days, with placebo raised by the user himself (anecdotal) — https://x.com/AJA_Cortes/status/1794522474702336108
39. Ten years of on-and-off use and a flat negative verdict (anecdotal) — https://x.com/LtCrandog/status/2082758463407473109
40. Eight weeks for a shoulder, judged not a success — but stomach problems returned after stopping (anecdotal) — https://x.com/WayneLMarsh/status/2081368522601509373
41. An injection-site problem from using too large a needle (anecdotal) — https://x.com/FreezerBurnv2/status/2080030523506806963
42. openFDA adverse event reports naming ibuprofen and naproxen (FAERS, queried 2026-08-04) — https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:%22ibuprofen%22&count=patient.reaction.reactionmeddrapt.exact


---

# BPC-157: Body Protection Compound

slug: bpc-157 · https://miscsubjects.com/a/bpc-157 · tags: peptide, bpc-157, disc, tendon, gut · updated 2026-08-04T20:44:21.585Z

If you have a disc that is wearing out, you are deciding between things that slow the wearing and things that claim to rebuild. BPC-157 is sold as the second kind. BPC-157 is a short chain of 15 amino acids copied from a protein found in human stomach juice. Around 150 animal papers, mostly rats, report it speeding repair in tendon, ligament, muscle, nerve, bone and gut. Five studies have been run in people, covering about 130 people in total, and none of them was a finished controlled trial in a torn or worn-out tissue. It has never been approved as a medicine anywhere. It is banned in sport at all times. Nobody has ever tested it on a spinal disc, in a rat or in a person.

One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason.
## The two clocks running in your back

A disc has two parts. The soft centre (the *nucleus pulposus*) is a water-holding gel that takes the load. Around it is a tough ring of layered fibres that keeps the gel where it belongs. Degeneration is the gel losing water and the ring cracking, in that order, over years.

Three things drive that.

The first is blood supply, or the near-absence of it. A disc is the largest structure in your body with no blood vessels running into it. Nutrients seep in through the bone plates above and below, and waste seeps out the same way. Those plates harden and clog with age. Once they do, the centre of the disc is a long way from any food supply, and cells in the middle start dying of the thing every tissue dies of when the plumbing fails.

The second is water. The gel holds water because of long sugar-protein molecules packed inside it. Cells make those molecules; dying cells stop making them. Less of them means less water, less water means a flatter disc, and a flatter disc loads its ring unevenly.

The third is the tearing itself. The ring is under shear every time you bend. When the centre stops cushioning, the ring takes load it was never built for, splits, and lets gel push out into the space where nerve roots run. That is a herniation, and the leg pain that follows is a squeezed nerve root (*radiculopathy*).

What makes it break down faster: smoking, which narrows the same small vessels feeding the bone plates; sustained loading without recovery; obesity; a genetic hand you did not choose, which explains more of the variation than most people expect; and — this is the one worth knowing before you read the rest of this page — steroid injections, which reliably reduce pain and reliably make the tissue heal worse.

Set against that, regeneration in a disc means one of three things: cells surviving longer, cells making more of the water-holding molecules again, or the ring physically closing. Every claim made for BPC-157 in a back is a claim about the first two, made by way of the blood supply. Nobody claims it closes a torn ring.

## Made in the stomach, and it survives the stomach

The name is literal: Body Protection Compound. The 15-piece chain is a fragment of a larger protein that sits in human stomach juice, and its one genuinely odd physical property is that it does not fall apart in that juice for more than 24 hours. Almost no peptide survives a stomach. That single property is the only reason a swallowed form is discussed at all, and it points at the gut as the compound's home ground.

Nearly the whole research record traces to one group in Zagreb, Croatia, led by Predrag Sikirić, running since 1993 and now past 150 papers.

That cuts both ways. It is a coherent, decades-deep programme applying one consistent dosing scheme across dozens of tissues, and it is also most of the world's evidence coming from a single group with a stake in the answer. It is the reason independent trials in people matter more here than they would for a compound many labs had poked at.

## What the different kinds of proof can and cannot tell you

Before the evidence, one table, said once, so the rest of the page does not have to keep apologising for itself.

| Kind of study | What it can settle | What it cannot settle |
|---|---|---|
| Cells in a dish | That the compound touches a specific switch inside a cell | Anything about a whole animal, a dose, or a person |
| Rats and dogs | That it changes a real injury in a living body, and by how much | Whether the same thing happens in a human, at what dose, or with what harm |
| Small safety studies in people | That a given dose did not visibly hurt a few dozen people over days | Whether it works, for anything |
| Chart reviews and phone follow-ups | What people remembered when asked | Whether the compound or the passage of time caused it |
| Randomised placebo trials | Whether it works | Nothing else needed — this is the one that settles it, and for a torn tissue none has finished |
| Forum and social posts | What exposure people are actually running, and what harms turn up at that exposure | Whether it works. Not weakly — not at all |


## Five studies in people, and the biggest one about an injury was a round of phone calls

FDA compiled the total published human experience for its July 2026 review. It is short enough to print in full.

| Study | How it was taken, and how much | People | Design | What happened |
|---|---|---|---|---|
| Healthy volunteers, rectal | up to 2 mg/kg daily × 8 days | 24 | Safety only | Nothing serious; headache and wind most common |
| Ulcerative colitis (Ruenzi 2005) | 80 mg rectal daily × 2 weeks | ~53 split into groups, ~26 treated | Randomised; published only as a conference abstract | Difference between groups 1.6 points, range −4.84 to 1.62 — the range crosses zero, so no effect was shown |
| Knee pain (Lee & Padgett 2021) | 2–4 mg into the joint, 1–2 injections | 17 found, 16 reached | Looked back at charts, then rang people up | 14 of 16 (87.5%) said they felt better; no dummy injection, no pain score, no scan |
| Interstitial cystitis | 10 mg into the bladder | 12 | No comparison group | Nothing serious reported |
| Healthy volunteers, into a vein | 10 mg then 20 mg | 2 | Safety pilot | No harm seen |

[[embed:source:w_9qu2rfyq]]

Two things fall out of that table and they are both worth sitting with.

The only randomised trial ever run on BPC-157 in a person was about an inflamed bowel, it exists only as a conference abstract, and the result range crosses zero — meaning the treated group and the untreated group cannot be told apart. And the only published report of BPC-157 doing anything for a musculoskeletal injury in a human is somebody reading old charts and then telephoning the people in them.

[[embed:source:w_nfh8rh08]]

Eleven of twelve people who got BPC-157 alone in that knee series said they improved a lot. There was no dummy injection, no random assignment, no standard pain questionnaire and no imaging. That is exactly the design that cannot separate a real drug effect from the well-known fact that sticking a needle into a sore knee makes people feel better for a while.

[[embed:source:s3]]

[[embed:source:s27]]

Two registered trials matter. A 2015 safety and absorption study in 42 healthy volunteers in Mexico gave single swallowed doses of 1 mg, 3 mg or 6 mg, then 3 mg every eight hours for two weeks. It never posted results, and the results submission was formally cancelled in 2016. Nobody knows what it found.

[[embed:source:w_rwwqkuud]]

The trial that could actually settle the tissue-repair question started recruiting in February 2026. It is randomised, double-blind, placebo-controlled, injected under the skin once a day for 14 days alongside a standard rehab programme, in 120 people aged 18–45 who have a grade II hamstring tear confirmed on a scan within 72 hours of doing it. The two things being measured are days until they can play sport again and the change in the size of the injury on the scan from day 0 to day 14. It is expected to finish in February 2027.

[[embed:source:s6]]

Until that reads out, there is nothing controlled in a human for any soft-tissue injury. Not weak data. None.

## Rats: what happened, in which tissue, at what dose

This is where nearly all the positive findings live. Read it as a picture of what the compound does in a living body when everything about the animal, the dose and the injury is controlled — and remember that the animals were young, healthy and injured on purpose, which is not your disc.

### A rat Achilles torn off the bone came back mechanically stronger

The join between tendon and bone is the hardest soft-tissue repair in the body and the one that most often fails. In rats whose Achilles tendon was surgically cut off the heel bone, BPC-157 raised the load the repair could take before failing, its stiffness and its springiness, all significantly above untreated animals. Under the microscope the collagen fibres were better lined up, there was more type I collagen — the strong, rope-like kind — and more blood vessels had grown in. Dose was 10 µg/kg, 10 ng/kg or 10 pg/kg into the belly cavity once a day, starting 30 minutes after surgery.

The same paper carries the finding most relevant to anyone who has already had a cortisone shot: the steroid 6α-methylprednisolone consistently made the healing worse, and BPC-157 substantially undid that damage.

[[embed:source:w_59xoi0m3]]

### Cut a ligament, crush a muscle, or sever the join between them — all three healed faster

The ligament model cut through the medial collateral ligament in rats and followed them 90 days. Treated animals came out ahead on four separate measures at once: how the leg worked, how strong the ligament was, how it looked to the eye, and how it looked under the microscope. Three different ways of giving it each worked — injection into the belly cavity at 10 µg/kg or 10 ng/kg daily, a cream at 1.0 µg per gram rubbed on, and plain drinking water at 0.16 µg/mL.

[[embed:source:w_ccsq5zep]]

The muscle model both cut through and crushed the rat calf muscle, and deliberately gave the animals a steroid to wreck the healing. The authors' finding is that BPC-157 completely reversed that steroid damage, given either by injection or as a cream, with the leg working normally again in treated animals.

[[embed:source:w_gttxaz57]]

The place where muscle turns into tendon — a classic site of grumbling strain that never settles — got its own study. In treated rats the injured leg's stiffening resolved completely, while untreated animals stayed disabled. The muscle wasting seen in untreated animals was prevented. By days 28 to 42 the new tissue ran in the right direction instead of being bridged by scar. Both the microgram and the nanogram doses worked.

[[embed:source:w_urj74cu2]]

The biggest recent study, from January 2025, pulled the quadriceps entirely off its bony anchors and then treated the rats only through their drinking water. The vastus muscles reattached as early as 21 days. Rectus femoris was back to normal anatomy at about 28 days. At three months the mature fibres ran parallel to the bone and sat right against it. Reattachment was tracked on ultrasound — the same imaging used on people.

[[embed:source:w_67ce14vu]]

The review that swept this whole literature screened 544 papers and kept 36. Thirty-five of the 36 were animal or lab work. Across muscle, tendon, ligament and bone the results point the same way: better function, better structure, better mechanical strength. The same authors put the counterweight in the same breath — harm is possible from unregulated manufacturing, contamination, and the fact that safety in people is unknown.

[[embed:source:w_bburqn2u]]

### A cut sciatic nerve regrew faster, which is the nearest thing to a nerve finding

Rats with a completely severed sciatic nerve got 10 µg/kg or 10 ng/kg into the belly cavity, into the stomach, locally at the repair site, or loaded straight into the tube bridging a removed segment. Self-mutilation of the dead-feeling limb — the standard sign that a rat's nerve pain is bad — did not happen in treated animals. Electrical testing showed stronger muscle signals. Weekly walking tests improved. Counting fibres under the microscope found more of them, thicker, with better insulation around them, at one to two months.

[[embed:source:w_032xvatb]]

Read what that is and is not. It is a nerve cut clean through and sewn back together. It is not a nerve being slowly squashed by a bulging disc or a tight tunnel in the wrist. No study of BPC-157 in a squashed or chronically compressed nerve has ever been published. The difference is not a technicality: a cut-and-repaired nerve has to regrow along a clear path, and a squashed nerve has to survive a mechanical problem that is still there. Different problems, different bottlenecks.

### Nobody has ever tested it on a disc

Two rat spinal-cord studies exist and both squash the cord itself, not a disc.

The 2019 study opened the spine at L2–L3 and compressed the tail end of the cord for 60 seconds, then gave a single injection into the belly cavity ten minutes later at 200 µg/kg or 2 µg/kg. Treated rats got progressively better tail movement, did not self-mutilate, and their spasticity had resolved by day 15, with less swelling and fewer dead motor nerve cells in the grey matter.

[[embed:source:s127]]

The 2022 follow-up is the more interesting one, because it waited before treating. After a one-minute squash by a 60–66 g weight that definitely paralysed the tail, one group got 2 µg/kg into the belly cavity at ten minutes. A second got a 10 ng/kg dose into the stomach on day 4. A third drank 10 µg/kg in water from day 4 to day 30. Recovery was described as fast and lasting out to a full year, with only patchy swelling, minimal bleeding and no loss of nerve insulation at day 30. Treatment started four days late still worked — which matters, because nobody turns up at a clinic ten minutes after their back goes.

[[embed:source:w_dmscp9sw]]

Neither of those is a disc. There is no published study of BPC-157 in a herniated or worn-out disc, in any species. And the doses used in the spinal work run up to a hundred times the doses used in the tendon work, so you cannot even carry a number across.

The argument people make for the disc goes like this: the disc has almost no blood supply, its healing is therefore limited by blood supply, and BPC-157's main proposed action is growing new blood vessels — so it should help. That argument is coherent. It also has no animal model behind it, let alone a human one. Nobody has put this compound in a degenerating disc and looked.

There is one more wrinkle worth stating, because it runs the other way. A worn disc is not supposed to have blood vessels in it. Part of what goes wrong in a painful disc is that vessels and pain nerves grow *into* the cracked ring, from the outside in, and that ingrowth is one of the better-supported explanations for why some worn discs hurt and others do not. A compound whose headline action is growing new vessels is being proposed for a tissue where new vessel growth is part of the pain. Nobody has tested which way that lands.

## How the compound is supposed to build tissue back

Strip the marketing and the proposed action is a short chain you can check link by link.

BPC-157 raises the signals that grow new blood vessels at an injury. New vessels bring oxygen and repair cells to tissue that had neither. Alongside that, it pushes collagen production and gets tissue-building cells to crawl into the gap.

The receptor step has been worked out in detail. In the cells that line blood vessels, BPC-157 makes the cell pull VEGFR2 — the main docking point for the body's chief vessel-growing signal — inside itself, and then switches on the VEGFR2–Akt–eNOS chain over time. Block the pulling-inside step with a chemical called dynasore and the whole effect disappears, which means the pulling-inside is required, not incidental. Vessel density went up both in a dish and in living animals, and blood flow came back faster in muscle that had been starved of it.

[[embed:source:w_fo79e9nk]]

The crawling step has its own named mechanism. In tissue-building cells taken from rat tendon, BPC-157 dose-dependently added phosphate groups to two proteins, FAK and paxillin, which are the machinery a cell uses to grip a surface and haul itself along. The total amount of those two proteins did not change; only the switched-on fraction rose. The same study found the cells were not making more of themselves, so the effect is cells moving and surviving, not cells multiplying in number.

[[embed:source:w_ud0jx8hb]]

A third mechanism sits underneath both. Tendon cells given BPC-157 at 0.5 µg/mL grew about seven times more growth hormone receptors by day three, measured both as the instruction and as the finished protein. The cell does not get more growth hormone. It gets better at hearing the growth hormone already going past.

[[embed:source:w_y4s15wvm]]

Nitric oxide — the gas that makes vessels widen — is pushed up in some situations and down in others, always paired with mopping up damaging free radicals. The Zagreb group reads that two-way behaviour as the whole point of the molecule: it pushes tissue toward normal rather than in one fixed direction. FDA reads the same observation as the reason no dose-response curve has ever been drawn for it. Both readings fit the data.

[[embed:source:s38]]

Now map that chain onto your disc, honestly. Link one, new vessels: real, shown in cells and in rats, never in a disc. Link two, vessels feeding a starved tissue: real in muscle, never shown in a disc, and a disc is starved through hardened bone plates rather than through missing vessels, which is a different blockage. Link three, cells making the water-holding molecules again: never studied for this compound, in any tissue. The chain has a hole in the middle of it exactly where your problem is.

## The painkiller you are probably already taking runs the opposite way to expected

Most people who arrive with back pain are already on an anti-inflammatory, and most compounds interact badly with those. This one was studied as an antidote to them.

Diclofenac at 12.5 mg/kg into the belly cavity once daily for three days produced severe stomach, gut and liver damage in rats, raised bilirubin, AST and ALT, made the liver heavier, and caused prolonged drowsiness that progressed to liver-driven brain failure with brain swelling and damaged nerve cells. BPC-157 blocked that entire cascade at both the microgram and the nanogram dose, given either by injection or in drinking water.

[[embed:source:w_odtbasyy]]

Read carefully, that is a gut-and-liver protection finding, not proof that combining the two heals a tendon better. What it does mean is that the medicine most likely to already be in the room is not, in rats, a documented problem.

The steroid interaction is the more useful one for a back. Two separate studies show BPC-157 undoing the damage a corticosteroid does to healing tendon and muscle. If you have had a cortisone injection into a joint or around a nerve root, the animal data says that shot measurably impaired the repair you went in for, and that this compound reversed that impairment in rats. That is the single most relevant animal finding on this page for a person with a degenerating spine, because so many people arrive having already had the shot.

## It is gone from your blood in about fifteen minutes

The only published measurements of what the body does to this compound come from rats and beagles.

Average time to clear half of it: 15.2 minutes. In dogs given it into a vein, 5.27 minutes. Peak level in the blood arrived three minutes after an injection into muscle. How much reaches the blood after an injection into muscle (bioavailability) was 14–19% in rats and 45–51% in dogs — wildly different between two species, and far from all of it. It leaves in urine and bile. Levels in kidney, liver, stomach wall, thymus and spleen went well above the level in blood.

[[embed:source:w_n7ahbrni]]

A compound cleared that fast cannot be working by keeping a steady level in your blood. Whatever it does, it does fast and locally, then sets off a slower tissue process that outlasts the exposure by weeks. Two practical things follow. First, that is the argument for splitting a daily dose rather than taking it all at once. Second, a once-a-week schedule has nothing behind it.

No measurement of any of this has ever been made in a person. Every number in this section is a rat or a dog, carried across species by assumption.

## Turning powder into a dose is arithmetic, not judgement

BPC-157 arrives as a freeze-dried white powder in a sealed glass vial, usually 5 mg or 10 mg. You add liquid to it. The liquid is bacteriostatic water — sterile water with 0.9% benzyl alcohol in it as a preservative, which is the thing that lets you put a needle into the same vial repeatedly over weeks. Plain sterile water dissolves the powder fine but has no preservative, so that vial is a one-time proposition.

The measuring device is a U-100 insulin syringe. U-100 means 100 units in a millilitre, so one unit on the barrel is 0.01 mL. Every conversion you will ever need comes from two lines:

- Micrograms per mL = total micrograms in the vial ÷ mL of water you added.
- Micrograms per syringe unit = that number ÷ 100.

Worked through: a 10 mg vial holds 10,000 mcg. You add 2 mL of bacteriostatic water. 10,000 ÷ 2 = 5,000 mcg per mL. 5,000 ÷ 100 = 50 mcg in one unit. A 250 mcg dose is therefore 250 ÷ 50 = 5 units on the barrel.

| Vial | Water added | Strength | Mcg per unit | Units for 250 mcg | Units for 500 mcg | Doses in the vial at 250 mcg |
|---|---|---|---|---|---|---|
| 5 mg (5,000 mcg) | 2.0 mL | 2,500 mcg/mL | 25 | 10 | 20 | 20 |
| 5 mg (5,000 mcg) | 2.5 mL | 2,000 mcg/mL | 20 | 12.5 | 25 | 20 |
| 10 mg (10,000 mcg) | 2.0 mL | 5,000 mcg/mL | 50 | 5 | 10 | 40 |
| 10 mg (10,000 mcg) | 3.0 mL | 3,333 mcg/mL | 33.3 | 7.5 | 15 | 40 |
| 10 mg (10,000 mcg) | 5.0 mL | 2,000 mcg/mL | 20 | 12.5 | 25 | 40 |

Adding more water does not add or remove peptide. The vial holds what it holds. More water only changes how many syringe units carry a given dose. More water gives you bigger, easier-to-read unit counts and a slightly bigger squirt going in. Less water gives you a smaller sting and finer lines to misread. Below about 5 units per dose, the error in reading a U-100 barrel starts to swamp the dose itself — which is the practical argument for putting 3 mL rather than 2 mL into a 10 mg vial.

Ruining the peptide by accident is easy. Let the vial come to room temperature first. Run the water slowly down the inside wall of the glass rather than blasting it onto the powder. Swirl until it dissolves. Never shake it — shaking tears at the surface where liquid meets air, which unfolds peptide chains and makes them clump together, and clumping is the exact thing FDA named as the trigger for the immune system reacting to it (immunogenicity).

## The clock starts the moment you add water

| State | Temperature | How long it actually lasts |
|---|---|---|
| Sealed, still a powder | 2–8 °C, out of the light | Months to years, to the maker's date; −20 °C for long holding |
| Mixed with bacteriostatic water | 2–8 °C | About four weeks — that limit is set by the preservative, not the peptide |
| Mixed, left on the counter | 20–25 °C | Hours to days; treat it as ruined |
| Mixed, then frozen | −20 °C | Do not. Freezing and thawing clumps the peptide |

Do the arithmetic against your own plan before you buy. A 10 mg vial at 250 mcg a day is 40 doses. Four weeks is 28 doses. You will throw away roughly a third of the vial, or you must buy a smaller one, or take more per day. There is no fourth option — refreezing it is the one thing that definitely damages it.

## Where the needle goes was never settled, because nobody asked the animals

Two placements compete and the animal work cannot referee between them, because rats were dosed into the belly cavity, into the stomach or rubbed on the skin, almost never at a specific human-style injection site.

- **Under the skin, near the sore part.** What most people do. The argument is a higher concentration where the repair is needed, which fits a 15-minute clearance and fits tissue levels running above blood levels.
- **Under the skin of the belly, anywhere.** Standard for gut, nerve and organ targets, and easier to do to yourself. The argument is that a compound reaching kidney, liver and stomach wall above blood level obviously travels, so the entry point may not matter.

The evidence tilts slightly toward the entry point not mattering. Several of the strongest structural results in the entire literature — the cut ligament, the muscle-tendon junction, the quadriceps reattachment, the sciatic nerve, the spinal cord — were produced in rats that simply drank the compound and still repaired a specific injury a long way from their gut. Nothing anywhere in the record shows a local injection beating a systemic one head to head.

Here are the doses that exist, all of them either from rats or scaled up from rats:

| Where the number comes from | The dose | How long |
|---|---|---|
| The standard rat tier | 10 µg/kg, 10 ng/kg or 10 pg/kg once a day | For as long as the study ran |
| The rat drinking-water equivalent | 0.16 µg/mL in water, about 12 mL per rat per day | For as long as the study ran |
| Scaling 10 µg/kg straight up to a 70 kg adult | about 0.7 mg per day | Not an established human dose. Just arithmetic |
| Given to humans into a joint, published | 2–4 mg per injection, 1–2 injections | One course |
| Given to humans by mouth, published (2015 Phase 1) | 1, 3 or 6 mg once; then 3 mg every 8 hours | Two weeks |

There is no validated human dose, no validated cycle length, no taper and no ceiling. USADA states it without softening: nobody knows whether a safe dose exists, or whether there is any way to use this compound safely for a named condition.

[[embed:source:w_af5ht9pr]]

Now notice what the table shows, because it is the single most overlooked fact about this compound. Every dose ever given to a human in a published study is measured in **milligrams**. Scaling the standard rat dose up to an adult lands at roughly 0.7 mg. The regimens circulating on forums and printed on vendor sites are measured in **micrograms** — a thousandth of a milligram — and land around 250 to 500 mcg. That is roughly a hundredth of anything ever formally given to a person. Nothing in the literature supports the microgram regimens. Nothing in the literature refutes them either. The dose question is not contested; it is simply open, and everyone taking it is guessing.

## The tablet and the vial are not the same product

Swallowed BPC-157 exists as capsules or tablets, commonly 500 mcg each, and the stomach-survival finding is what makes that format arguable at all. But surviving your stomach acid and getting into your bloodstream are two separate questions, and only the first has ever been shown in a person.

| | Tablet you swallow | Vial you mix and inject under the skin |
|---|---|---|
| What is actually proven about this route | Survives human stomach juice past 24 hours | In rats, 14–19% of an injection into muscle reaches the blood; in dogs, 45–51% |
| Animal evidence using this route | Substantial — the ligament, muscle-tendon junction, quadriceps reattachment, nerve and spinal cord studies all worked with the compound given by mouth or in water | Extensive, but nearly all of it into the belly cavity rather than under the skin |
| What has been given to humans this way | 1–6 mg by mouth in the 2015 Phase 1; 80 mg per enema in the colitis trial | 2–4 mg into a joint; 10–20 mg into a vein |
| Best-supported target | The gut, and any whole-body target where the rat drinking-water arm worked | Musculoskeletal — by convention, not by any head-to-head comparison |
| How much gets into a human's blood | Never measured | Never measured |
| What it costs you in practice | No needles, no mixing, no four-week clock | Needles, arithmetic, a fridge, and a four-week clock |

The evidence is friendlier to the swallowed route than the injection convention implies. Several of the strongest structural repair results in the whole corpus — ligament, muscle-tendon junction, muscle reattached to bone, delayed spinal cord recovery — came from rats drinking it in water. What nobody has is a measurement of how much of a swallowed dose gets into a human's blood, so choosing between the two forms rests on rat route data and on convenience, not on anything measured in a person.

## How long anything would take, if it worked

Timelines here are set by tissue biology, not by the compound. Collagen remodels at the speed collagen remodels. Nerves regrow at about a millimetre a day. Nothing changes that.

| Model | Time to the reported result |
|---|---|
| Squashed spinal cord, spasticity gone | 15 days |
| Quadriceps reattached to bone, vastus muscles | 21 days |
| Quadriceps reattached to bone, rectus femoris | ~28 days |
| Muscle-tendon junction, tissue running the right way | 28–42 days |
| Cut sciatic nerve, function and microscope findings | 1–2 months |
| Cut medial collateral ligament, full follow-up | 90 days |
| Hamstring tear Phase 2, injury size on scan | 14 days (the primary measure; reads out 2027) |

No human timeline has been established, because no controlled human trial has finished.

The one inference that is honest: these are collagen and nerve timescales — four to twelve weeks. Anything promising a result inside a fortnight is describing pain relief, not repair. That distinction has a consequence you can act on. Pain relief arrives before tissue has been rebuilt. If you feel better at day 10 and go back to loading your spine on that signal, you are loading a structure that has not changed.

## FDA's own toxicology is more specific than the safety talk around it

The Zagreb group's stated position is that BPC-157 is very safe, with no side effects in trials and a lethal dose never reached in toxicology work. FDA read the same body of work and described it differently.

In 28-day repeat-dose studies injecting into muscle, rats showed shortened clotting time and dogs showed lengthened clotting time on the same test — an unexplained effect on clotting that runs in opposite directions in two species. Blood ALT, glucose and triglycerides went up. No cancer-causing study of BPC-157 in either of its two chemical forms has ever been done. It did not damage DNA, and no birth-defect signal appeared when it was injected through gestation days 6–15.

FDA raised four objections. They are independent of each other, which means answering one leaves the other three standing.

| The objection | What it actually means |
|---|---|
| Not enough clinical safety information to describe the safety profile | The human safety file is too small to draw a picture from — not "reassuring so far", but too small to say anything |
| Real risk that the immune system reacts to it, made worse by clumping and by peptide impurities | Part of the risk comes from how it is made and handled, not from the molecule alone |
| No dose-response relationship established | The flat pattern where micrograms, nanograms and picograms all work reads to FDA as a weakness, not a feature |
| No molecular target identified | Despite the VEGFR2 and FAK work, no confirmed receptor has been pinned down |

[[embed:source:w_9qu2rfyq]]

## The cancer question has a real answer and a real hole in it

The worry is mechanically sensible. A tumour cannot grow past a millimetre or two without recruiting new blood vessels. A compound whose headline action is growing new blood vessels could, in principle, supply them. An independent 2025 review states the worry and lands on the practical version of it: a cancer nobody has found yet.

[[embed:source:w_uhm2s5ar]]

The Zagreb group published a formal rebuttal in the same journal. Their case is that BPC-157 strongly *blocked* vessel growth into the cornea, that it has shown anti-tumour activity both in living animals and in a dish, and that its nitric oxide effect is always paired with mopping up free radicals — that it pushes vessel growth toward the normal, self-limiting kind rather than driving it indiscriminately.

[[embed:source:s131]]

Where that leaves you: no published rodent study shows BPC-157 speeding up tumour growth. No cancer-causing study exists. There is zero human cancer safety data. An active or suspected cancer is the one situation the mechanism itself argues against, and the missing study means the argument cannot be closed either way. If you have had a cancer, this is the question to take to your oncologist rather than to a forum.

## FDA said no, and its own advisory committee said yes by two votes

The regulatory position moved twice during 2026, and most summaries you will find online are stale.

| Date | What happened |
|---|---|
| Sept 2023 | FDA puts BPC-157 in Category 2 of the 503A bulk-substances list — significant safety risk, which bars compounding pharmacies from making it |
| 14 May 2026 | The revised interim list carries only six substances in Category 2. BPC-157 is in none of Categories 1, 2 or 3 — the nominations were withdrawn |
| July 2026 | FDA's own briefing document recommends against adding BPC-157 to the 503A list |
| 23 July 2026 | The Pharmacy Compounding Advisory Committee votes 8–6, with one abstention, to recommend adding it — against FDA's own staff |

If a page you are reading still says BPC-157 is FDA Category 2, it has not been updated since 14 May 2026.

[[embed:source:w_ghpbaz64]]

One detail in the meeting agenda changes what that vote means. The only condition FDA evaluated was ulcerative colitis. Tendonitis was among the uses put forward, and FDA declined to evaluate it because there was not enough information. A favourable vote about a bowel condition is not a favourable vote about tendon or disc repair, and it is being quoted as though it were.

[[embed:source:w_38qd7eam]]

The committee itself was not persuaded of much. One panelist who voted yes described the thing being voted on as a black box. One who voted no pointed out that roughly 30% of people given a dummy treatment report improvement — sometimes even on objective measures — which is the entire difficulty with the uncontrolled reports the nomination rested on.

[[embed:source:w_oje4lc91]]

Reporting on the meeting noted that a majority of the panelists voting yes had ties to the peptide industry.

[[embed:source:w_lkfuwkh8]]

The vote creates no authority. It is advisory, FDA is not bound by it, and a formal rulemaking cycle realistically runs eight to twelve months.

[[embed:source:s129]]

## There are two legal ways to compound a peptide and BPC-157 is on neither list

503A covers traditional compounding pharmacies. 503B covers registered outsourcing facilities, and it is a separate list with a separate standard: an outsourcing facility may not compound with a bulk substance unless that substance is on the 503B list, or the finished medicine is on FDA's drug shortage list at the time. BPC-157 is not on the 503B list, and the July 2026 vote concerned 503A only.

[[embed:source:w_iff2eacs]]

That same page sets out what FDA expects of any lawfully compounded substance: a valid certificate of analysis, manufacture by an establishment registered under section 510 of the FD&C Act, and compliance with any applicable USP or National Formulary monograph. Grey-market BPC-157 meets none of the three.

## If you compete in anything, this is a strict-liability problem

BPC-157 is named explicitly on the WADA 2026 Prohibited List under S0, Non-Approved Substances, banned at all times — not just on competition day. S0 covers any substance with no current approval by any government health authority for human use anywhere, which is exactly what BPC-157 is.

[[embed:source:w_u19qrezt]]

Strict liability means you are responsible for what is in your body regardless of intent and regardless of who recommended it. That applies at college, professional and masters level, in sports most people do not think of as drug-tested.

The Department of Defense goes further. Its Operation Supplement Safety programme lists BPC-157 on the Prohibited Dietary Supplement Ingredients List and states the position flatly: BPC-157 is not a dietary ingredient, it is an unapproved drug. That applies to service members however it is taken.

[[embed:source:w_h2eu8h3c]]

## "Research use only" is a shipping label, not a legal category

Nearly all BPC-157 sold to the public is labelled a research chemical, not for human consumption. That phrase creates no lawful route to a person. It is a disclaimer attached to a product with no legal standing as a medicine, a food or a supplement in the United States. USADA names the tell directly: sites that print "research only" while also printing human dosing instructions are describing what they expect to happen.

The purity problem is the concrete risk, and it is bigger than the legal one. Independent testing of grey-market peptide samples finds mislabelling, wrong dosing or contamination in roughly 30%, and the contaminant classes are specific: bacterial toxins, incomplete chains that are missing pieces, leftover solvents, heavy metals, live microbes and breakdown products. Incomplete chains and clumping are the same two failure modes FDA named as the things that make an immune reaction more likely — which means the supply-chain risk and the drug risk are the same risk wearing two hats.

[[embed:source:w_macsi7l3]]

> 30% contained incorrect amino acid sequences and two-thirds of samples fell below the 95% purity threshold.

[[embed:source:s130]]

A certificate reading "99% by HPLC" does not clear a batch, and understanding why is worth two minutes. HPLC confirms the target peptide is there and measures how much of the total it is. It says nothing about what the other 1% consists of. An incomplete chain or a fever-causing bacterial toxin sits inside that remainder and never shows up. What you want is HPLC *and* mass spectrometry, done per batch, by a laboratory that is not the seller. A vendor's own certificate is not third-party testing, and a certificate photographed from a different batch is not a certificate at all.

## Which problems the evidence actually reaches

Every positive animal model in this literature is an acute surgical injury — a tendon cut through, a ligament severed, a muscle crushed, a tendon torn off bone, a nerve cut. There is no rat model of a fifteen-year grumbling tendon, and no reason to assume a repair signal helps tissue whose problem is failed remodelling rather than an unfilled hole.

| Your problem | What the animal data actually covers | How strong |
|---|---|---|
| Fresh tendon tear or rupture | Achilles cut through and torn off bone: strength to failure, stiffness, type I collagen all improved | Strongest animal case |
| Tendon pulling off bone | Achilles detachment and quadriceps reattachment, confirmed on ultrasound at 21–28 days | Strong in animals, nothing in humans |
| Ligament sprain | Medial collateral ligament cut through, 90-day follow-up, four measures | Strong in animals, nothing in humans |
| Fresh muscle strain | Calf muscle cut and crushed; the one Phase 2 trial targets a grade II hamstring | Animals plus one trial reading out 2027 |
| Pain where muscle becomes tendon | Its own rat model; stiffening resolved, wasting prevented | Strong in animals, nothing in humans |
| Healing spoiled by a cortisone shot you already had | Two studies show the steroid damage to tendon and muscle healing reversed | Animals, directly relevant, nothing in humans |
| You are on daily anti-inflammatories | Diclofenac damage to gut, liver and brain fully blocked | Animals; a protection finding, not a repair finding |
| Nerve cut and surgically repaired | Sciatic nerve: electrical signals, walking, insulation all improved | Moderate in animals, nothing in humans |
| Long-standing overuse tendon pain | No model exists. Every positive study is a fresh injury | Weak — the mechanism does not obviously apply |
| Carpal tunnel or other trapped nerve | No compression model exists | Absent |
| Herniated lumbar disc, sciatica | No disc model exists. Nearest thing is a squashed rat spinal cord at a 100× dose | Absent |
| Degenerative disc disease itself | Nothing. Not one study, in any species | Absent |

Three rows carry the weight and they are not the three people expect.

The cortisone-reversal row is the most useful finding in the entire animal literature, because a large share of people with a bad back arrive having already had a steroid injection that measurably worsened the healing they came in for. If any part of this compound's animal record applies to you, that is the part with the clearest logic behind it.

The long-standing-tendon-pain row is weak exactly where demand is highest.

And the two disc rows are empty. The problem people ask about most is the one with no animal model at all — and, as the next section shows, it is also one of the problems that generates the loudest success stories.

## Fifty people said what happened to them, and here is the count

Everything above this heading is evidence. Everything below it is testimony, and the difference is not a matter of degree.

This page holds 50 first-person accounts posted publicly between 2015 and 2026 — 40 on Reddit across r/Peptides, r/steroids, r/backpain, r/Sciatica, r/climbharder, r/PEDs, r/Biohackers, r/moreplatesmoredates, r/PeptideGuide, r/Peptidesource and r/Supplements, and 10 on X. Every one is self-reported by a person you cannot identify or question. Nobody assayed their vial, so the substance in the syringe is unknown in every single case. Nobody was randomly assigned. Almost nobody scanned the injury before and after. People who got better write posts more often than people who did not, so the set is filtered before you even read it.

It is here for one reason. No controlled trial in a human musculoskeletal injury has ever finished, so this is the entire record of people using it for the reasons you are considering it — and it is what you have already read by the time you got to this page.

### The count, with the denominator

Of the 50 accounts, 13 report no personal result at all — they are protocols, questions, general threads about the science, or one person's dosing accident. That leaves **37 accounts that state what happened to the person writing**. Here is the split:

| What they reported | Count | Share of the 37 |
|---|---|---|
| It helped — clear improvement they credit to it | 18 | 49% |
| Partly, or it faded, or they could not separate it from other things | 5 | 14% |
| Nothing happened | 10 | 27% |
| It made something worse | 4 | 11% |

Read that table twice. Half of the people who reported an outcome said it helped, and half did not. If you have seen this compound described online, you have almost certainly seen a version of that record where the 14 accounts reporting nothing or harm were left out. That version is a lie by selection, and it is the standard version.

Four more things the raw count hides.

The 10 "nothing happened" accounts are not shorter courses or smaller doses than the successes. Several ran six weeks or more at the same 500 mcg a day that the successes ran.

The 4 harm reports describe things the rat toxicology gives no reason to expect and the five human studies were far too small to catch: a joint that got worse and inflamed, vision going blurry over weeks, a finger swelling with fluid, and leg pain returning during treatment for a herniated disc.

One account reports a ten-fold dosing accident, which is a safety datapoint of its own and the reason the reconstitution arithmetic earlier on this page matters more than it looks.

And exactly one account in 50 reports an objective check by a clinician. One. Everybody else is reporting pain, movement and confidence — the three things most responsive to time, rest and expectation.

### The 18 who said it helped

[[embed:source:w_xmo3vo5n]]

[[embed:source:w_xypc4fgc]]

[[embed:source:w_ihoinuk1]]

[[embed:source:w_iquapnzf]]

[[embed:source:w_vhlzhg4n]]

[[embed:source:w_mez2amn7]]

[[embed:source:w_z8sd87d2]]

[[embed:source:w_5icolfqk]]

[[embed:source:w_8uy508st]]

[[embed:source:w_e1ub04di]]

[[embed:source:w_as6ue9dv]]

[[embed:source:w_e8sw6xul]]

[[embed:source:w_qqu8pdaq]]

[[embed:source:w_q512lyfs]]

[[embed:source:s82]]

[[embed:source:s83]]

[[embed:source:s93]]

[[embed:source:s101]]

Two of those deserve a note rather than applause. The account crediting a clinician with saying the tear was gone is the single best entry in the whole set, and even that was a re-examination, not a repeat scan. And the account that asks itself "is this placebo?" also added collagen and more protein in the same window, which the writer says outright — that honesty makes it more useful than the confident ones, not less.

### The 5 who got part of a result, or lost it

[[embed:source:w_sg898nqt]]

[[embed:source:w_vljlka3r]]

[[embed:source:w_q3b1i12c]]

[[embed:source:w_iqb7rlvn]]

[[embed:source:w_brwijbo1]]

The last one is a pattern with no counterpart anywhere in the published literature: the effect fading on a steady dose, then not returning when the dose was raised. Nothing in the rat work predicts that. Nothing in the pharmacology explains it.

### The 10 who said nothing happened

These are the entries marketing copy leaves out. They are the same doses, the same durations, and several of them are longer courses than the successes.

[[embed:source:w_jdqqio36]]

[[embed:source:w_fhil2can]]

[[embed:source:w_8dxl599w]]

[[embed:source:w_0t8zcb1s]]

[[embed:source:w_txuoas2j]]

[[embed:source:w_9l5g0ldo]]

[[embed:source:w_8kdirxz8]]

[[embed:source:w_18w5khoc]]

[[embed:source:w_hf6dcwyh]]

[[embed:source:w_mjx06qhj]]

The standard reply offered inside these threads to a negative report is that the person got a bad vial. That reply cannot be checked — nobody in this set tested their product — and it is the exact mechanism by which a grey-market compound builds a record that can never fail. Every success counts as evidence; every failure counts as a counterfeit.

### The 4 who got worse

[[embed:source:w_epyzmnva]]

[[embed:source:w_ucf38h39]]

[[embed:source:w_usaqx7am]]

[[embed:source:w_0d8jnd1s]]

The first of those is the one to read closely if you have a disc problem: leg pain returning and worsening during a course taken specifically to heal a herniated disc. That is the exact situation this page is about, and it is a harm report, not a success.

The second describes one joint improving while another got inflamed and worse in the same person, on the same dose, in the same course.

### The dosing accident, and where the numbers came from

[[embed:source:w_wnund5ki]]

That is ten times the intended dose, caused by misreading a syringe barrel. Nobody was hurt. It is on this page because the numbers everyone uses have nothing under them, and the people using them say so plainly:

[[embed:source:w_o9okgjxa]]

[[embed:source:w_mzg8md2j]]

[[embed:source:w_xk3kn65m]]

[[embed:source:w_1t3oc07y]]

Almost every account in the set describes 250 to 500 micrograms a day, under the skin, sometimes split into two or three shots, run for four to eight weeks. That band converged by copying, not by measurement. It is about a hundredth of the milligram doses used in every published human study.

### The 13 that report no outcome at all — including the six loudest posts here

Thirteen of the 50 accounts state no personal result. Seven are the protocols and dosing arguments already shown above. The other six are X posts, and they are worth looking at separately, because they are almost certainly the format in which most people first meet this compound.

[[embed:source:s88]]

[[embed:source:s89]]

[[embed:source:s99]]

[[embed:source:s100]]

[[embed:source:s95]]

[[embed:source:s96]]

Read what those six actually are. Four are summaries of the animal literature written in the voice of personal endorsement — "repaired 5 different tissues", "no compound heals as many tissue types" — with a dose attached at the end and no report of the writer's own outcome anywhere in them. One is a person asking for an alternative. One is a person saying they never took it but wish they had.

They are in this count because leaving them out would be dishonest, and they are separated out because counting them as successes would be worse. The most confident writing about this compound contains the least first-hand information in it, and that is the single most useful thing this section can tell you.

### Where the accounts contradict the animal work

The animal record is strongest for fresh injuries and weakest — or empty — for long-standing tendon pain and for discs.

The forum record inverts that exactly. Long-standing elbow, wrist and shoulder tendon pain of one to five years' standing is the most common thing people treat. Herniated discs and sciatica — the problem with no animal model whatsoever — generate some of the most emphatic success reports on this page.

The single most emphatic disc account on this page — the sciatica report above, in which pain eased over six to seven weeks of injections after everything else had failed — is also the one with the least behind it, because no animal has ever been given this compound for a disc.

Two readings fit that and the accounts cannot separate them. Either the compound reaches structures the animal work never tested, or long-standing pain that comes and goes was going to improve anyway and the compound arrived during a good month. The disc reports are the clearest case, because a herniated disc shrinks on its own in a large share of people over roughly six to twelve weeks — which is exactly the window these protocols run. Somebody who starts a course at their worst week and finishes it feeling better has described the natural history of the condition, and would have written the same post taking nothing.

The swallowed route contradicts the pharmacology the same way. Surviving stomach acid is proven; getting into a human's blood from the gut is not. People report the two forms doing different jobs, which is precisely what you would expect if the tablet works locally in the gut and never reaches a tendon at all.

[[embed:source:w_1bbc6bfn]]

### The stacking problem, which is the biggest hole in the whole set

Almost nobody takes this alone. TB-500 is combined with it so routinely that a large share of these accounts cannot attribute any outcome to either compound. Others add growth hormone, testosterone, surgery, physiotherapy, diet changes and rest inside the same weeks.

[[embed:source:w_ahk1cevh]]

The three most confident recovery stories on this page — the rotator cuff tear a clinician later called gone, the wrist rebuilt over seven vials, and the shoulder that felt 75% better in five days — were all run as BPC-157 plus TB-500, and two of them alongside structured rehab. Not one of them can tell you which part did the work.

That is not a small caveat. It means a good share of the 18 positive accounts are reports about a combination, run alongside the two interventions with the best evidence in all of musculoskeletal medicine — load management and time.

### What the counted record settles, and what it does not

It does not settle whether it works. Thirty-seven uncontrolled accounts filtered toward success are not weak evidence for a treatment effect; they are a different kind of object, and collecting three hundred more would change nothing about that. A 49% success rate in this set is not a 49% chance it works for you. It is a measurement of what people wrote down.

It does settle three things the published literature does not contain at all, and these are the reason it is worth counting rather than dismissing.

First, the real exposure. People are running 250–500 mcg a day under the skin for four to eight weeks, usually stacked with TB-500. No trial has ever studied that exposure. When somebody eventually does, this is the regimen they should test, and nobody would know it from the papers.

Second, harms at that exposure. Four of 37 accounts report getting worse — local swelling, a joint becoming more inflamed, blurred vision, and returning nerve pain. None of those appear in any published human safety dataset, because those datasets total about 130 people across five studies and would not detect a 1-in-10 problem if it existed.

Third, the mismatch. The two things people actually treat with it — long-standing tendon pain and lumbar disc disease — are the two the animal literature supports least and not at all, respectively.

The Phase 2 hamstring trial reading out in 2027 will answer the works-or-not question for one fresh injury in one muscle. Nothing currently running will answer it for a disc.

## What is settled about BPC-157, and what is not

| Status | Statement |
|---|---|
| Settled | It survives human stomach juice for more than 24 hours |
| Settled | It switches on the VEGFR2–Akt–eNOS chain and increases blood vessel density in a dish and in rodents |
| Settled | It improves mechanical strength and microscope appearance across many fresh rat injuries |
| Settled | It reverses the damage a corticosteroid does to tendon and muscle healing in rats |
| Settled | It blocks diclofenac-caused gut, liver and brain damage in rats |
| Settled | Half of it clears a rat's blood in about 15 minutes; 14–19% of an intramuscular dose reaches the blood in rats |
| Settled | It is on the WADA 2026 Prohibited List under S0, banned at all times, in and out of competition |
| Not shown | That it does anything for a musculoskeletal injury in a person — no controlled soft-tissue trial has finished |
| Not shown | That a swallowed dose reaches the bloodstream of a human |
| Not shown | That it feeds tumours — and equally not shown that it is safe if you have a cancer |
| Unknown | The right human dose. Every published human study used milligrams; everyone taking it uses micrograms |
| Unknown | Long-term safety, interactions with your other medicines, and why clotting time moves in opposite directions in rats and dogs |
| Unknown | Whether any of this reaches a spinal disc. Nobody has looked, in any species |

If you take one line from this page, take this one: the strongest argument for BPC-157 in a degenerating back is a chain of reasoning, and the strongest argument against it is that nobody has ever tested a single link of that chain in a disc. The animal work is real and it is good. It is also about tendons, ligaments, muscles and cut nerves in young rats injured on purpose, and your disc is none of those things.

*BPC-157 is not an approved medicine in any country. Everything sold to the public is grey-market and unverified. Nothing here is a dosing or treatment recommendation.*

The sibling objects for this page, each one inspectable on its own terms:

[[embed:tb-500]]

[[embed:ara-290]]

[[embed:kpv]]

[[embed:wolverine-stack]]

[[embed:bpc-157-vs-nsaids]]

[[embed:what-are-peptides-herniated-disc]]

[[embed:herniated-disc]]


## Sources

1. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing — https://pubmed.ncbi.nlm.nih.gov/30915550/
2. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study — https://pubmed.ncbi.nlm.nih.gov/40131143/
3. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing — https://pubmed.ncbi.nlm.nih.gov/40789979/
4. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review — https://pubmed.ncbi.nlm.nih.gov/40005999/
5. BPC 157 for Acute Hamstring Muscle Strain Repair — https://clinicaltrials.gov/study/NCT07437547
6. Emerging Use of BPC-157 in Orthopaedic Sports Medicine — https://journals.sagepub.com/doi/abs/10.1177/15563316251355551
7. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity — https://pmc.ncbi.nlm.nih.gov/articles/PMC11053547/
8. Peptide BPC-157 - Does It Work? Breaking Down ... — https://www.youtube.com/watch?v=HIrI8STJPJo
9. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — https://pubmed.ncbi.nlm.nih.gov/40756949/
10. Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT) — https://pubmed.ncbi.nlm.nih.gov/40759852/
11. SELFTEST graph fn ingest
12. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — https://pubmed.ncbi.nlm.nih.gov/41476424/
13. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing — https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
14. Multifunctionality and Possible Medical Application of the Stable Gastric Pentadecapeptide BPC 157 — https://www.mdpi.com/1424-8247/18/2/185
15. What Science ACTUALLY Says About BPC 157 Benefits — https://www.youtube.com/watch?v=gaQwrB8HW4o
16. The Role of BPC-157 in Tissue Repair and Pain Management — https://pubmed.ncbi.nlm.nih.gov/41898733/
17. Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review — https://pubmed.ncbi.nlm.nih.gov/41754849/
18. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review — https://pmc.ncbi.nlm.nih.gov/articles/PMC11859134/
19. BPC-157 – No Proof Required! — https://www.mcgill.ca/oss/article/medical-critical-thinking-health-and-nutrition-contributors/body-protection-compound-no-proof-required
20. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management — https://pmc.ncbi.nlm.nih.gov/articles/PMC13026520/
21. Pentadecapeptide BPC 157 and the central nervous system — https://pubmed.ncbi.nlm.nih.gov/34380875/
22. BPC-157: Miracle Healing Peptide or Hidden Danger? — https://www.orthoandwellness.com/blog/bpc-157-update-and-deep-dive-miracle-healing-peptide-or-hidden-danger
23. BPC-157 and the Difference Between an Evidence Gap and a Cover-Up — https://wellfounded.health/insights/bpc-157-and-the-difference-between-an-evidence-gap-and-a-cover-up
24. Stable Gastric Pentadecapeptide BPC 157 and Striated, ... — https://pubmed.ncbi.nlm.nih.gov/36551977/
25. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide — https://pubmed.ncbi.nlm.nih.gov/41155565/
26. S808 Oral Peptide BPC-157—An Emerging Adjunct to Gastrointestinal Therapies? — https://journals.lww.com/ajg/fulltext/2025/10002/s808_oral_peptide_bpc_157_an_emerging_adjunct_to.809.aspx
27. Peptides in Orthopedics: BPC-157 — What Patients Should Know About Safety, Efficacy, and Sourcing — https://www.mdorthospecialists.com/2026/04/28/peptides-in-orthopedics-bpc-157-what-patients-should-know-about-safety-efficacy-and-sourcing/
28. How does the Peptide BPC-157 Work? — https://www.youtube.com/watch?v=WjCtQM_rfBE
29. Stable Gastric Pentadecapeptide BPC 157 as a Therapy of ... — https://pubmed.ncbi.nlm.nih.gov/40573323/
30. Stable Gastric Pentadecapeptide BPC 157 as a Therapy of ... — https://pubmed.ncbi.nlm.nih.gov/41832718/
31. Stable Gastric Pentadecapeptide BPC 157 as Therapy ... — https://pubmed.ncbi.nlm.nih.gov/39861766/
32. Protective Effects of BPC 157 on Liver, Kidney, and Lung ... — https://pmc.ncbi.nlm.nih.gov/articles/PMC11857380/
33. Peptides and BPC-157 for Pain: What's the deal? — https://www.youtube.com/watch?v=-rIoG_UF6RI
34. Tracheocutaneous Fistula Resolved by Pentadecapeptide ... — https://pmc.ncbi.nlm.nih.gov/articles/PMC12844668/
35. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection — https://pubmed.ncbi.nlm.nih.gov/38980576/
36. Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats — https://pubmed.ncbi.nlm.nih.gov/39861766/
37. Safety of Intravenous Infusion of BPC157 in Humans — https://pubmed.ncbi.nlm.nih.gov/40131143/
38. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — https://pubmed.ncbi.nlm.nih.gov/41476424/
39. The Role of BPC-157 in Tissue Repair and Pain Management — https://pubmed.ncbi.nlm.nih.gov/41898733/
40. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing — https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
41. Of all the peptides I've tried BPC-157 is my favorite. — https://x.com/mindpumpsal/status/1751417750806020447
42. BPC-157 post — https://x.com/Breedlove22/status/2071613094540030205
43. PEPTIDE MASTERCLASS: BPC-157 — https://x.com/KingOfVitamins/status/2071610257093145038
44. BPC-157 tendon healing details — https://x.com/KingOfVitamins/status/2071610274843332656
45. TB-500 with BPC-157 for tissue repair — https://x.com/Breedlove22/status/2071613106678337793
46. X post by @mariioo888 — https://x.com/mariioo888/status/2071633910514212931
47. X post by @TakeThiamine — https://x.com/TakeThiamine/status/2071621198287610002
48. X post by @BasedBiohacker — https://x.com/BasedBiohacker/status/2027900122026414320
49. X post by @HealthyAlfred — https://x.com/HealthyAlfred/status/2042931532688494967
50. X post by @WovenDissent — https://x.com/WovenDissent/status/2071612933382037588
51. BPC 157 promotes tendon healing via outgrowth, cell survival, and migration — https://pubmed.ncbi.nlm.nih.gov/21030672/
52. BPC 157, in clinical trials for IBD (PL14736), heals colocutaneous fistulas in rats — https://pubmed.ncbi.nlm.nih.gov/18818478/
53. BPC 157 improves the healing course of spinal cord injury and leads to functional recovery in rats — https://pmc.ncbi.nlm.nih.gov/articles/PMC6604284/
54. BPC-157 Legal Status 2026: FDA Category 2 Removal, PCAC Review — https://lotilabs.com/resources/bpc-157-legal-status-2026-fda-update/
55. An FDA Committee Just Voted in Favor of Peptides-Despite the Agency's Opposition (TIME) — https://time.com/article/2026/07/23/fda-committee-peptides/
56. Gray-Market Peptides: The 'Research Use Only' Fiction — https://rethinkpeptides.com/articles/for-research-use-only-the-legal-fiction-of-gray-market-peptides
57. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide (review commentary) — https://pmc.ncbi.nlm.nih.gov/articles/PMC12567428/
58. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation — https://pubmed.ncbi.nlm.nih.gov/27847966/
59. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration — https://pubmed.ncbi.nlm.nih.gov/21030672/
60. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts — https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/
61. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat — https://pubmed.ncbi.nlm.nih.gov/20225319/
62. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation — https://pubmed.ncbi.nlm.nih.gov/16583442/
63. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application — https://pubmed.ncbi.nlm.nih.gov/20190676/
64. Stable gastric pentadecapeptide BPC 157 as a therapy for the disabled myotendinous junctions in rats — https://pmc.ncbi.nlm.nih.gov/articles/PMC8615275/
65. Stable gastric pentadecapeptide BPC 157 as therapy after surgical detachment of the quadriceps muscle from its attachments for muscle-to-bone reattachment in rats — https://pmc.ncbi.nlm.nih.gov/articles/PMC11768438/
66. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs — https://pmc.ncbi.nlm.nih.gov/articles/PMC9794587/
67. Intra-articular injection of BPC 157 for multiple types of knee pain — https://pubmed.ncbi.nlm.nih.gov/34324435/
68. Phase I, pilot study in healthy volunteers, to assess the safety and pharmacokinetics of PCO-02 (BPC-157) — https://clinicaltrials.gov/study/NCT02637284
69. FDA briefing document, Pharmacy Compounding Advisory Committee: evaluation of BPC-157-related bulk drug substances for inclusion on the 503A bulk drug substances list — https://www.fda.gov/media/193343/download
70. Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act — https://www.fda.gov/media/94155/download
71. July 23-24, 2026: meeting of the Pharmacy Compounding Advisory Committee — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
72. World Anti-Doping Code International Standard: Prohibited List 2026 — https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
73. BPC-157: experimental peptide creates risk for athletes — https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/
74. BPC-157: a prohibited peptide and an unapproved drug found in health and wellness products — https://www.opss.org/article/bpc-157-prohibited-peptide-and-unapproved-drug-found-health-and-wellness-products
75. FDA panel votes to loosen restrictions for four peptides — https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides
76. FDA advisory panel narrowly votes to allow compounding of unapproved peptides — https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/
77. What's changing with peptide regulation in 2026 — https://www.bscg.org/blogs/single/whats-changing-with-peptide-regulation-in-2026
78. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review — https://pubmed.ncbi.nlm.nih.gov/40756949/
79. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review — https://pmc.ncbi.nlm.nih.gov/articles/PMC11859134/
80. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury — https://pubmed.ncbi.nlm.nih.gov/19903499/
81. Novel therapeutic effects in rat spinal cord injuries: recovery of the definitive and early spinal cord injury by the administration of pentadecapeptide BPC 157 therapy — https://pmc.ncbi.nlm.nih.gov/articles/PMC9164058/
82. Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions — https://pubmed.ncbi.nlm.nih.gov/21295044/
83. Bulk drug substances used in compounding under section 503B of the FD&C Act — https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act
84. Compound experience saturday bpc157 — https://www.reddit.com/r/steroids/comments/7zy7yi/compound_experience_saturday_bpc157/duz790a/
85. Does bpc157 increase recovery between workouts — https://www.reddit.com/r/moreplatesmoredates/comments/1kfp3uf/does_bpc157_increase_recovery_between_workouts/mr860tt/
86. Compounds healing compounds bpc157 tb500 etc — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi6t9l6/
87. Chronic onesided thoracic pain — https://www.reddit.com/r/backpain/comments/1ccysh4/chronic_onesided_thoracic_pain/
88. Hlab27 sacroiliitis on mri vs disc obliteration — https://www.reddit.com/r/backpain/comments/1mu96us/hlab27_sacroiliitis_on_mri_vs_disc_obliteration/
89. Compounds to help articular cartilage fissure in — https://www.reddit.com/r/PEDs/comments/173pdv4/compounds_to_help_articular_cartilage_fissure_in/
90. Need help deciding between kpv low dose — https://www.reddit.com/r/Peptidesource/comments/1v6e4g2/need_help_deciding_between_kpv_low_dose/
91. Blend experience — https://www.reddit.com/r/Biohackers/comments/1u7ixcd/blend_experience/
92. Ligament injury repair with bpc157 and tb500 — https://www.reddit.com/r/moreplatesmoredates/comments/phepeu/ligament_injury_repair_with_bpc157_and_tb500/hsp96nl/
93. Bpc 157 and tb 500 for herniated disc — https://www.reddit.com/r/backpain/comments/1fi50ar/bpc_157_and_tb_500_for_herniated_disc/
94. Bpc157 gone wrong — https://www.reddit.com/r/PEDs/comments/1qftcul/bpc157_gone_wrong/
95. 1 month of bpc157 tb500 blend reviewblurry vision — https://www.reddit.com/r/Biohackers/comments/1ra2m3p/1_month_of_bpc157_tb500_blend_reviewblurry_vision/
96. Bpc157 for shoulder injury — https://www.reddit.com/r/Biohackers/comments/1tufuie/bpc157_for_shoulder_injury/
97. I know some will disagreebut new batch of bpc 157 — https://www.reddit.com/r/Biohackers/comments/1u7ddu1/i_know_some_will_disagreebut_new_batch_of_bpc_157/
98. Bpc157 and tb4 has it not worked for you — https://www.reddit.com/r/Peptides/comments/1uute3b/bpc157_and_tb4_has_it_not_worked_for_you/
99. De quervains tendonitis recovery — https://www.reddit.com/r/PEDs/comments/1isdmz1/de_quervains_tendonitis_recovery/
100. Finally got around to trying the bpc157 capsules — https://www.reddit.com/r/Supplements/comments/1rcxvm9/finally_got_around_to_trying_the_bpc157_capsules/
101. Need guidance — https://www.reddit.com/r/PeptideGuide/comments/1s4vose/need_guidance/
102. Compounds healing compounds bpc157 tb500 etc — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi9owhr/
103. Compound experience saturday bpc157 — https://www.reddit.com/r/steroids/comments/7zy7yi/compound_experience_saturday_bpc157/dus0n8q/
104. Compound experience saturday bpc157 — https://www.reddit.com/r/steroids/comments/7zy7yi/compound_experience_saturday_bpc157/dutyok7/
105. And it begins bpc 157 and tb 500 — https://www.reddit.com/r/backpain/comments/1khc6p5/and_it_begins_bpc_157_and_tb_500/nokzab3/
106. Bpc 157 drinking reconstituted injectable vs — https://www.reddit.com/r/Peptides/comments/1u8m20w/bpc_157_drinking_reconstituted_injectable_vs/osdrkbj/
107. Experience with bpc157 and elbow tendinopathy — https://www.reddit.com/r/climbharder/comments/1j4fiij/experience_with_bpc157_and_elbow_tendinopathy/
108. My experience case study recovering from an a2 — https://www.reddit.com/r/climbharder/comments/1axf2aa/my_experience_case_study_recovering_from_an_a2/
109. Compounds healing compounds bpc157 tb500 etc — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi3v7kp/
110. Compounds healing compounds bpc157 tb500 — https://www.reddit.com/r/steroids/comments/150bge2/compounds_healing_compounds_bpc157_tb500/js5hfcw/
111. Compounds healing compounds bpc157 tb500 etc — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4eq0n/
112. Compounds bpc157 my experience — https://www.reddit.com/r/steroids/comments/tqsoik/compounds_bpc157_my_experience/
113. Compounds healing compounds bpc157 tb500 etc — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4uao6/
114. Bpc 157 tb500 side effect for 65 yrs old — https://www.reddit.com/r/Biohackers/comments/1u09ium/bpc_157_tb500_side_effect_for_65_yrs_old/oqhs3hp/
115. Compounds healing compounds bpc157 tb500 etc — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4iwuk/
116. Lifting 3 months after a broken wrist — https://www.reddit.com/r/moreplatesmoredates/comments/1l697k3/lifting_3_months_after_a_broken_wrist/
117. Accidentally took 30iu of bpc157 instead of 3iu — https://www.reddit.com/r/Peptides/comments/1teo1c6/accidentally_took_30iu_of_bpc157_instead_of_3iu/
118. Bpc157 and tb500 weekly update — https://www.reddit.com/r/Biohackers/comments/1sgf3q0/bpc157_and_tb500_weekly_update/
119. Is oral bpc157 less effective than injecting it — https://www.reddit.com/r/PEDs/comments/1o3g7qp/is_oral_bpc157_less_effective_than_injecting_it/niwej2s/
120. Pinched sciatic nerve — https://www.reddit.com/r/Sciatica/comments/1rnicr5/pinched_sciatic_nerve/
121. Bpc157 for herniated disc l5 s1 — https://www.reddit.com/r/Sciatica/comments/uk0bhk/bpc157_for_herniated_disc_l5_s1/
122. Bpc157 saved my foot — https://www.reddit.com/r/Supplements/comments/1scedge/bpc157_saved_my_foot/
123. Bpc157peptides in general — https://www.reddit.com/r/climbharder/comments/lvmkqd/bpc157peptides_in_general/kcrhbqv/